Official Title:  A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and 
Efficacy of the Second  Mitochondrial -derived Activator of Caspases (SMAC) 
Mimetic Debio 1143, When Given in  Combination with the Anti-PD-[ADDRESS_81005] Progressed 
During or Immediately After Anti-PD-1/PD -L1 Treatment  
NCT Number:  NCT04122 625 
Document  Date : Protocol Version 4: 07 April 2020 
  
 
 
 
STUDY PROTOCOL  
 
 
SMARTPLUS -106: Debio 1143 a SMAC Mimetic in Combination with Nivolumab in 
Patients Failing Prior PD -1/PD -L1 Treatment: A Basket Trial   
A dose -optimization, exploratory phase Ib/II study to assess safety and efficacy of the  Second 
Mitochondrial -derived Activator of Caspases  (SMAC ) mimetic Debio 1143, when given in 
combination with the anti -PD-[ADDRESS_81006]  progressed during or immediately after anti -PD-1/PD -L1 treatment  
 
Investigational Medicinal Product (IMP): Debio [ADDRESS_81007] (IMP): Nivo lumab  
Study Number: Debio [ADDRESS_81008] N umber: 2018 -003546 -16 
US IND Number:  105074  
 
 
SPONSOR:  
Debiopharm International SA  
Forum "après -demain"  
Chemin Messidor [ADDRESS_81009](s) (IRB) / Independent Ethics Committee(s) 
(IEC) reviewing the protocol. No information can be provided to a third party without the written 
agreement of Debiopharm International SA, except medical personnel directly concerned by [CONTACT_74290].  
 | Page 1/107

Protocol    3/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 TABLE OF CONTENTS  
1. INTRODUCTION  27 
2. PHARMACEUTICAL AND B ACKGROUND INFORMATIO N 27 
2.1. Nivolumab  ................................ ................................ ................................ ...........  27 
2.2. Debio 1143 ................................ ................................ ................................ ..........  28 
2.2.1.  Chemical structure, formula, and molecular weight  ................................ ............  28 
2.2.2.  International non -proprietary name, brand name, and code name  .....................  28 
2.2.3.  Mechanisms of action  ................................ ................................ ........................  28 
2.3. Brief summary of non -clinical and clinical data  ................................ ....................  28 
3. RATIONALE AND RISK B ENEFIT ASSESSMENT  30 
4. STUDY OBJECTIVES  31 
4.1. Primary objectives  ................................ ................................ ...............................  31 
4.1.1.  Part A  ................................ ................................ ................................ ................  31 
4.1.2.  Part B  ................................ ................................ ................................ ................  31 
4.2. Secondary objectives  ................................ ................................ ..........................  31 
4.2.1.  Part A  ................................ ................................ ................................ ................  31 
4.2.2.  Part B  ................................ ................................ ................................ ................  31 
4.3. Exploratory objectives  ................................ ................................ .........................  31 
5. STUDY DESIGN AND TRE ATMENT  32 
5.1. Study design  ................................ ................................ ................................ ....... 32 
5.1.1.  Part A  ................................ ................................ ................................ ................  32 
5.1.2.  Part B  ................................ ................................ ................................ ................  33 
5.2. DLT period and definition of DLTs  ................................ ................................ ....... 34 
5.3. Study treatments  ................................ ................................ ................................ . 34 
5.4. Dose modifications  ................................ ................................ ..............................  36 
6. STUDY POPULATION  39 
6.1. Inclusion criteria  ................................ ................................ ................................ .. 39 
6.2. Exclu sion criteria  ................................ ................................ ................................ . 40 
6.3. Patient replacement  ................................ ................................ ............................  42 
7. CLINICAL SUPPLIES  42 
7.1. Investigational medicinal products  ................................ ................................ ....... 42 
7.1.1.  Debio 1143  ................................ ................................ ................................ ........  42 
7.1.2.  Nivolumab  ................................ ................................ ................................ .........  42 
7.2. Packaging a nd storage of IMPs  ................................ ................................ ...........  42 
7.2.1.  Packaging  ................................ ................................ ................................ .........  42 
7.2.2.  Labeling  ................................ ................................ ................................ .............  42 
7.2.3.  Storage  ................................ ................................ ................................ ..............  43 
7.3. Dispensing and accountability of IMPs  ................................ ................................  43 
7.4. Patient numbering  ................................ ................................ ...............................  43 
7.4.1.  Screening number  ................................ ................................ .............................  43 
7.5. Blinding and unblinding methods  ................................ ................................ .........  43 
7.6. Method of administration and compliance  ................................ ...........................  44 
 | Page 3/107

Protocol    4/[ADDRESS_81010] -study  ................................ ................................ .........................  77 
9.3. Follow -up of serious adverse events  ................................ ................................ ... 77 
9.4. Procedure for SAE communication  ................................ ................................ ..... 78 
9.5. Pregnancies  ................................ ................................ ................................ ........  78 
10. MONITORING AND STUDY  COMMITTEES  78 
10.1.  Monitoring  ................................ ................................ ................................ ...........  78 
10.2.  Study committees ................................ ................................ ................................  78 
10.2.1.  Data Safety Monitoring Committee  ................................ ................................ .... 78 
11. DATA MANAGEMENT AND STATISTICAL ANALYSIS  79 
11.1.  Sample size  ................................ ................................ ................................ ........  79 
11.2.  Data management and handling  ................................ ................................ .........  79 
11.2.1.  Data capture, verification and validation  ................................ ............................  79 
11.2.2.  Missing data handling for statistical analysis ................................ ......................  80 
11.3.  Handling of values below (or above) a threshold  ................................ .................  80 
11.4.  Handling of unscheduled assessments or retests ................................ ................  80 
 | Page 4/107

Protocol    5/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 11.4.1.  Derived parameters and endpoints  ................................ ................................ .... 80 
11.5.  Selection of patients for statistical analysis  ................................ .........................  82 
11.5.1.  RP2D population (part A only)  ................................ ................................ ...........  [ADDRESS_81011] / Independent Ethics Committee  ................................  89 
12.3.  Informed consent  ................................ ................................ ................................  89 
12.4.  Patient confidentiality  ................................ ................................ ..........................  89 
12.5.  Data reporting and electronic case report forms  ................................ ..................  89 
12.6.  Retention of data  ................................ ................................ ................................ . 90 
12.7.  Deviations from the protocol/protocol amendments  ................................ .............  90 
12.8.  IMP accountability  ................................ ................................ ...............................  90 
12.9.  Study monitoring  ................................ ................................ ................................ . 90 
12.10.  Sponsor audits  ................................ ................................ ................................ .... 91 
12.11.  Regulatory agency inspections  ................................ ................................ ............  91 
12.12.  Publications  ................................ ................................ ................................ .........  91 
12.13.  Insurance policy  ................................ ................................ ................................ .. 91 
12.14.  Premature study termination  ................................ ................................ ...............  91 
13. REFERENCES  92 
14. APPENDICES  95 
14.1.  Appendix A: World Medical Association Declaration of Helsinki  ..........................  95 
14.2.  Appendix B: Prohibited medications and special warnings  ................................ .. 98 
14.3.  Appendix C: Response to treatment criteria  ................................ ......................  103 
 
TABLE OF TABLES  
 
Table 1 -1 Schedule of assessments  ................................ ................................ .....................  20 
Table 5 -1 Days of treatment for each treatment cycle  ................................ ...........................  35 
Table 5 -2 Study treatment starting doses  ................................ ................................ ..............  36 
Table 5 -3 Re-treatment criteria  ................................ ................................ .............................  37 
Table 7 -1 Treatment modification for symptoms of infusion -related reactions associated with 
nivolumab  ................................ ................................ ................................ .........................  45 
Table 7 -2 Management of immune -related AEs  ................................ ................................ .... 46 
Table 8 -1 Sampling days and times for PK on Cycle 1  ................................ ..........................  63 
Table 8 -2 Sampling days and times for PK (for Cycle 3 exclusively, irrespective of nivolumab 
schedule switch)  ................................ ................................ ................................ ...............  64 
Table 8 -3 Sampling day and times (for Cycle 6 and EOT exclusively, irrespective of 
nivolumab switch of schedule)  ................................ ................................ ..........................  65 
Table 8 -4 Sampli ng days and times for PDy and biomarkers  ................................ ................  67 
 | Page 5/107

Protocol    6/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 Table 8 -5 Windows of tolerance for PK, PDy and biomarker samples  ................................ ... 67 
Table 8 -6 Schedule of assessments  ................................ ................................ .....................  69 
Table 11 -1  Metrics and corresponding values  ................................ ................................ ..... 86 
Table 11 -2 Futility Early stoppi[INVESTIGATOR_74239]  ................................ ................................ ...... 86 
Table 11 -3 Boundaries for declaring efficacy  ................................ ................................ ....... 86 
 
 
 
 | Page 6/107

Protocol    7/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 STUDY SYNOPSIS  
STUDY TITLE  SMARTPLUS -106: Debio 1143 a  SMAC Mimetic In Combination With Nivolumab In 
Patients Failing Prior PD -1/PD -L1 Treatment: A Basket Trial  
A dose -optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second 
Mitochondrial -derived Activator of Caspases  (SMAC)  mimetic Debio 1143, when given in 
combination with the anti -PD-[ADDRESS_81012] progressed during or immediately after anti -PD-1/PD -L1 treatment  
STUDY NUMBER  Debio [ADDRESS_81013] 
NUMBER  2018 -003546 -16 
US IND NUMBER  105074  
STUDY PHASE / 
INDICATION  Phase Ib/II  / Basket trial in selected solid tumors  
PARTICIPATING 
COUNTRIES AND 
NUMBER OF SITES  Part A - Up to six active sites in [LOCATION_009] and Spain  
Part B - In addition to Part A sites, up to 10 sites in the US. 
(Full list to be provided separately ) 
STUDY DESIGN  This study consists of two sequential parts:  
1. Part A: a dose -optimization phase Ib  
2. Part B: an exploratory phase II basket trial  
 
Part A  has an open -label, multicent er and dose -optimization design applying the classical 
3+[ADDRESS_81014] doses 
of nivolumab (OPDIVO®) in order to define a safe recommended phase II dose (RP2D) and 
to assess its safety and feasibility in pretreated patients with selected advanced/unresectable 
solid tumors, including : small cell lung cancer (SCLC); squamous cell carcinoma of the head 
and neck (SCCHN); known microsatellite  instability -high (MSI -H), mismatch repair 
deficiency (MMRd) or other  known  DNA damage repair  (DDR) abnormalities, including 
homologous recombination  deficiency (HRD) in gastrointestinal (GI) cancers; known DNA 
MMRd/MSI -H, breast cancer (BRCA) -1/2 hereditary or somatic/sporadic mutations, or other 
DDR abnormalities including HRD in platinum -resistant ovarian, endometrial, primary 
peritoneal or cervical  cancers. Patients must have received  at least one prior systemic line of 
standard treatment and  must  have progressed or relapsed during or immediately after a prior 
anti-programmed cell death -1 (PD -1)/ programmed cell death -ligand 1 (PD -L1)-based  
treatment, given either as a single agent or in combination with standard/approved 
chemotherapy, tyrosine kinase inhibitors (TKIs) or other monoclonal antibodies (mAbs) that 
are not known to modulate/inhibit immune check points. P atients with p rior cytotoxi c T-
lymphocyte antigen 4 (CTLA -4) or lymphocyte activation gene -3 (LAG -3) combinations  
with PD -1/PD -L1 are excluded; any other prior combinations with checkpoint inhibitors 
(CPI) should be discussed and agreed by [CONTACT_74291].  
Eligi ble patients will enter the study in cohorts of three evaluable patients.  
The starting dose of Debi o 1143 will be 150 mg daily , administered orally for 10 consecutive 
days every 2 weeks (i.e., Days 1 -10 and Days 15-24 of each 28 -day cycle [q4w]). The d ose 
will be optimized according to the observed dose limiting toxicities (D LTs), patient treatment 
compliance, safety/ tolerability and pharmacokinetic s (PK) data, if applicable. The DLT 
period is defined as Cycle 1 (i.e. , lasting 4 weeks or longer in case of dosing delays). 
Treatment -related toxicities fulfilling DLT criteria but occurring after Cycle 1 (i.e., delayed 
DLTs) may also be considered for RP2D definition after discussion and agreement between 
the Investigators and the Sponsor.  
Nivolumab wil l be administered at [ADDRESS_81015] 30 minutes as an intravenous 
(IV) infusion  on Days [ADDRESS_81016] with  the Sponsor  agreement .  
 | Page 7/107

Protocol    9/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 (unconfirmed)  rate (ORR)  will be used.  In each cohort, i f no unconfirmed response is observed 
according to Response Evaluation Criteria in Solid  Tumors (RECIST v1.1)  or Gynecologic 
Cancer Intergroup ( GCIG ) criteria  (Cohort 4 ) once the initial  [ADDRESS_81017] one response  
(unconfirmed)  is documented in the initial [ADDRESS_81018] 15% . If homogeneous response rates are seen across the cohorts, efficacy data 
will be pooled,  and an overall efficacy analysis will be conducted  in addition to the analyses by 
[CONTACT_9084] . For the final analysis, first proof of efficacy will be claimed in a given cohort if at least 
4 objective responses  (confir med)  are reported in the 15 evaluable patients.  
In the case of insufficient accrual in a ny cohort ( e.g., less than 2 patients in 6 months)  despi[INVESTIGATOR_74240],  enrolment may be stopped in that 
cohort .  
A Data Safety Monitoring Committee (DSMC), composed at least of all actively involved 
investigators (or their designees ), the Sponsor Medical Director and the Contract Research 
Organization (CRO) medical monitor as voting members, will meet regularly to ov erview the 
clinical safety of the patients and laboratory data and the conduct of the study during both study 
parts A and B. Ad hoc members may be invited upon needed.  
During Part A , calls will be scheduled monthly or according to patient recruitment as n ecessary. 
A charter will be provided as a separate document.  
During Part B the DSMC will meet  approximately  every three months, and more frequently if 
needed in the event of  rapid recruitment. A charter will be provided separately.  
STUDY 
OBJECTIVES  Primary objectives  
Dose -optimization study (P art A):  
To determine the  RP2D taking into account  DLT/s in Cycle 1, overall  safety/tolerability and 
PK, by [CONTACT_74292] [ADDRESS_81019] treatments.  
Basket trial (P art B):  
To evaluate the preliminary anti -tumor activity of Debio [ADDRESS_81020] dose,  overall  and in each patient cohort.   
Secondary objectives  
Part A:  
1. To assess the PK disposition of Debio 1143  (and its metabolite  Debio 1143 -MET1 ) 
and nivolumab when administered in combination.  
2. To assess the anti -tumor activity of Debio 1143 in combination with nivolumab in 
patients with advanced solid malignancies . 
Part B :  
1. To assess the safety and tolerability of the RP2D of Debio 1143 when given  in 
combination with nivolumab in patients with advanced solid malignancies .  
2. To assess the PK disposition of Debio 1143  (including its metabolite Debio 1143 -
MET1)  and nivolumab when administered in combination . 
Exploratory objectives  
 To explore potential predictive and pharmacodynamic (PDy) biomarkers of 
Debio  1143 and nivolumab when administered in combination,  in blood and tumor  
tissue  
 
 
 
 | Page 9/107

Protocol    10/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
  To explore genetic variations in drug metabolism enzyme and transporter (DMET) 
genes associated with differences in the PK disposition of Debio 1143 in 
combination with nivolumab . 
 To explore the exposure/response relationship for efficacy and safety (including 
PK/PDy correlations, if applicable) of Debio 1143 in combination with nivolumab  
 To explore correlation s between response, clinical parameters, immune correlates, 
and putative biomarkers,  
 To explore the relationship between Debio 1143 plasma concentrations and QTcF  
ENDPOINTS  Primary:  
Part A:  
 RP2D of Debio [ADDRESS_81021] treatment  and 
failed  a prior PD -1/PD -L1-containing treatment,  as per DLT occurrence in less than 
one-third o f evaluable treated patients at the RP2D dose level .  
Part B:   
 Confirmed ORR as per RECIST v1.1  and/or GCIG criteria ( in Cohort 4, if applicable) . 
 
Secondary  (for both study parts  unless otherwise specified ): 
 Incidence and severity of TEAEs and clinical laboratory abnormalities , according to 
NCI-CTCAE v5.0  
 Changes in vital signs : systolic/diastolic blood pressure, heart rate (both after at l east 
[ADDRESS_81022]), temperature, and weight ; electrocardiograms (ECG) and 
Eastern Cooperative Oncology Group Performance Status (ECOG -PS) 
 Incidence of premature treatment discontinuations and treatment modifications due to 
TEAEs and laboratory abnormalities (i.e., treatment compliance).  
 Confirmed ( Part A) and unconfirmed (Parts A and B) ORR using standard RECIST 
v1.1 and/or GCIG criteria (Cohort 4, if applicable) .  
 Disease control rate  (DCR) , defined as any response, partial  response (PR)  or complete  
response (CR) , + stable disease (SD)  
 Time -related  endpoints as median time  to response, median duration of response 
(DOR ), median progression -free survival ( PFS), PFS rate at  6,12 and 18 months, 
median overall survival ( OS), OS rate at 12 months  and 18 months (if data allow ) 
 PK parameters of Debio [ADDRESS_81023] -hoc estimates of areas 
under the curve ( AUCs ), Cmax, and C min; serum concentration versus time profiles of 
nivolumab and,  if deemed appropriate, relevant nivolumab PK parameters  derived 
from a population PK model . 
Exploratory:  
 Potential predictive and PDy biomarkers  of Debio 1143 combined with nivolumab  in 
blood and tumor tissue   
 
 
 Best overall response ( BOR ) evaluation as per iRECIST criteria  2017 guideline for 
immunotherapeutics  
 Correlation s between PK disposition of Debio 1143 combined with nivolumab and 
clinical response and/or any tumor metrics  
 Correlation s between PK disposition of Debio 1143 combined with nivolumab and 
safety profile, an d PDy if applicable  
 Correlation s between Debio 1143 and Debio 1143 -MET1 plasma concentrations 
and changes from baseline QTcF.  
 Correlation s between response, clinical parameters, immune correlates and putative 
biomarkers,  
 Genetic variations in DMET genes associated with differences in the PK disposition 
of Debio 1143 in combination with nivolumab  
 | Page 10/107

Protocol    11/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 STUDY 
POPULATION  Patients with  selected  advanced /unresectable or metastatic solid tumors , for whom standard 
therapy has failed , including progression to prior treatments with anti PD -1/PD -L1 given as 
single agent or in combination with standard/approved chemotherapy , TKIs or other targeted 
agents, RT, hormonal therapy or any other non -CPI [INVESTIGATOR_74241], but excluding other antib ody or drug 
specifically targeting T -cell co -stimulation or immune checkpoint s pathways (i.e. , CTLA -4). 
Any other potential CPI [INVESTIGATOR_74242].  
The same indications will be eligible in both study Part A and B. In Part B, separate cohorts are 
defined as follows.  
Part A : 
 Between 3 and 12 patients evaluable for DLT planned.  
 Patients will be evaluable for DLT  if they received at least 70% of Debio 1143 and 
one planned nivolumab dose during Cycle 1 and were evaluated for DLT  or if the 
patient discontinu ed treatment  earlier due to any toxicity that could be considered a 
DLT.  
 Non-evaluable patients will be replac ed, as appropriate . 
 
Part B :  
Cohort 1 : SCLC  (including extrapulmonary small -cell carcinomas or large cell 
neuroendocrine lung carcinoma, as per WHO Classification of Lung Tumors of  2015)1 
Cohort 2: SCCHN  (nasopharyngeal carcinomas are excluded)  
Cohort 3 : GI cancers (including esophageal, gastric, colorectal or pancreatobiliary) with 
known  MSI-H/MMRd or other DDRs abnormalities, including HRD.  
Cohort 4 : platinum -resistant EOC, endometrial cancer, PPC or cervical cancer, with known 
MSI-H/MMRd, hereditary/somatic mutations of the BRCA1 and BRCA2 genes or other 
DNA DDR  abnormalities (incl. HRD ).  
 Between 32 (if all cohorts are futile) and 60 evaluable patients (if none of the 4 cohorts 
is futile).  
 Patients will be evaluable for efficacy if the two conditions below are met:  
a. Measurable disease at baseline as per RECIST v1.1  or GCIG criteria (Cohort 
4), 
b. At least one efficacy assessment  done , either  computed tomography ( CT) or 
magnetic resonance imaging ( MRI ) for RECIST evaluable patients; or CA -
125 dosage performed after baseline , if applicable  or treatment 
discontinuation occurred before  the efficacy assessment is done due to 
treatment failure , defined as any of the following : death, unacceptable 
toxicity , clinical deterioration and /or symptoms worsening.  
 Non-evaluable patients will be replaced.  
 
INCLUSION 
CRITERIA  The same tumor types are eligible in Part A and B . 
 
Patients must  fulfill  all the  following criteria  (in both Parts A and B, unless specified otherwise):  
 
1. Willing and able to sign a written informed consent form;  
2. Male or female ≥18 years of age.  
3. Histologically and/or cytologicall y confirmed advanced/ unresectable  or metastatic 
solid tumor , for one of the following indications . 
a. SCLC  
b. SCCHN  (nasopharyngeal carcinomas are excluded)  
c. GI cancers, including esophageal, gastric, colorectal or pancreatobiliary with 
known MSI -H/MMRd or any other known DDRs abnormalities, including 
HRD  
d. Platinum -resistant* EOC, endometrial cancer, PPC or cervical cancer, with 
known MSI -H/ MMRd, hereditary/so matic mutations of the BRCA1 and 
BRCA2 genes or other known DNA DDRs abnormalities (incl. HRD)  
 | Page 11/107

Protocol    12/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 * Platinum -resistant is defined as relapse or progressive disease (PD) 
occurring within 1 to 6 months (180 days) after a platinum -containing 
chemotherapy.   
4. Have  received at least one prior line of standard systemic chemotherapy in the 
advanced/unresectable cancer setting (standard adjuvant/neoadjuvant treatment is 
acceptable if relapse occurred within six months of treatment end) and have no 
established standard therapeutic alternatives  
5. Have progressed or relapsed during or after  a prior anti -programmed cell death -1 (PD -
1)/ programmed cell death -ligand 1 (PD -L1)-based  treatment, given either as a single 
agent or in combination with standard/approved chemotherapy, tyrosine kinase 
inhibitors (TKIs) , radiotherapy ( RT) or other monoclonal antibodies (mAbs) that are 
not known to modulate/inhibit immune checkpoints  (CPIs) . 
6. Minimum washout periods since prior thera py until treatment start (C1D1)  (in case s 
of more than one prior treatment type, whichever has the longest minimum period 
applies):   
a. 3 weeks for chemotherapy (6 weeks, specifically for nitros oureas or 
mitomycin C containing regimens)   
b. 4 weeks for any prior mAbs or live vaccines ; for investigational mAbs [ADDRESS_81024]  
c. 3 weeks for prior RT (1 week in case of localized antalgic/hemost atic 
hypofractionated RT flash)   
d. 2 weeks for TKIs, hormonal therapy, other anti -cancer treatment not 
previously specified or investigational agents  
e. 4 weeks for any major surgery  
f. Immunosuppressive medication: within 2 weeks, with the exception of 
intranasal and inhaled corticosteroids or systemic corticosteroids at 
physiological/replacement doses, which s hould never exceed 10 mg/d 
prednisone, or an equivalent corticosteroid  
7. Measurable disease (Part B  only) according to RECIST v1.1 and/or GCIG criteria in 
Cohort #4 (if applicable) and documented PD during or after prior PD -1/PD -L1 based 
therapy  
8. ECOG Perform ance Status  = 0 or 1   
9. Adequate hematologic, renal and hepatic function:  
a. absolute neutrophil count (ANC) ≥  1.5 x109/L,  
b. platelets ≥  100 x109/L,  
c. hemoglobin ≥ 9.0 g/dL,  
d. AST and ALT ≤ [ADDRESS_81025]  (≤ [ADDRESS_81026] if  liver metastases are present )   
e. total bilirubin ≤ 1.[ADDRESS_81027],  
f. serum creatinine  ≤ 1.[ADDRESS_81028],  
g. serum albumin ≥ 30 g/L  
10. Available archived tumor samples for biomarker analysis obtained after prior PD -
1/PD -L1 treatment failure or, if no archived tumor sample is available, patient must 
be suitable and willing to undergo a percutaneous or endoscopic biopsy without 
unacceptable major risks before starting study treatment  
11. Participants with known central nervous system (CNS) and/or meningeal involvement 
will be eligible if they  are clinically a symptomatic,  have completed primary CNS 
therapy more than 4 weeks before treatment start  (such as whole brain RT, stereotactic 
radiosurgery, or complete surgical resection),  and have remained off steroids 
(including tapering doses) for at least 2 weeks  
12. Wom en of child -bearing potential  (WOCBP) : 
a. Negative serum pregnancy test at screening;  
b. Agreement to use highly effective contraception methods from study entry 
and for up to [ADDRESS_81029] day of study treatment  
 
 | Page 12/107

Protocol    13/[ADDRESS_81030] NOT fulfill any of the following criteria (in both Parts A and B, unless specified 
otherwise):  
 
1. Thoracic or head and neck radiation >[ADDRESS_81031] received , in total,  more than 3  (i.e. Cohorts 1&2) or 4 (i.e.  Cohorts 3&4)  lines 
of prior systemic tre atments (including adjuvant or neoadjuvant regimens if relapse 
within six months  prior to C1D1 ) 
3. Active moderate alcohol consumption , at screening,  more than 100/140 grams 
(3.5/4.9 ounces) of alcohol per week for female / male patients, respectively  
4. Liver cirrhos is Child -Pugh score B or  C 
5. Prior tre atment with  an anti-CTLA -4 or anti -LAG3  in combination with PD -1/ PD -
L1 CPI , unless discussed and agreed with the Sponsor  
6. Prior treatment with SMAC mimetics  
7. Prior PD -1/PD -L1 discontinuation due to severe immune -related toxicity, not 
resolved upon adequate steroids/immunosuppressive treatment  
8. Requirement of concomitant treatment with any prohibited medication  (See 
Appendix B: Prohibited medications  and special warnings ) 
9. Ongoing  toxicity from prior administration of any other investigational drug and/or 
anti-cancer treatment of > Grade 1 NCI-CTC AE v5.0 before treatment start  (except 
for grade 2 alopecia , stable sensory neuropathy , vitiligo or any endocrinopathy 
adequately managed by [CONTACT_74293])   
10. Patients  with known history of:  
a. Uncontrolled or symptomatic angina or myocardial infarc tion, within the 
last 12 months  prior to C1D1  
b. Elevated (>U LN) troponins (T or I) or creatine phosphokinase ( CPK ) > 
1.5xULN  during screening  
c. Symptomatic intestinal sub -occlusion  
d. Infection , active or latent  by [CONTACT_74294] (HIV), 
hepatitis B  virus (HBV)  and hepatitis C  virus  (HCV)  
e. Ongoing arrhythmias requiring treatment, including asymptomatic  QTc 
interval  as corrected by [CONTACT_6550] (F)  >480 msec  
f. In patients previously treated with anthracycline -containing chemotherapy  
or thoracic RT, non -adequate cardiac function with left ventric ular ejection 
fraction (LVEF)  <50%, measured by [CONTACT_74295] (ECHO) or a 
multigated acquisition (MUGA) as per institutional standards  
g. Active rheumatoid arthritis, active inflammatory bowel disease (IBD), 
primary sclerosing cholangitis, autoimmune hepa titis, systemic lupus 
erythematous (SLE), multiple sclerosis or any other ongoing autoimmune 
disease requiring systemic treatment (excluding vitiligo, mild cutaneous 
psoriasis and asymptomatic autoimmune endocrinopathy well controlled 
under hormonal replac ement therapy)  
h. Evidence of active, non –infectious pneumonitis or a history of interstitial 
lung disease  
i. Active ongoing infection requiring systemic antibiotic therapy, including 
active tuberculosis   
11. Evidence or clinical suspi[INVESTIGATOR_74243] 
(RBC) transfusions wi thin [ADDRESS_81032]  1 year prior to C1D1 , except:  completely resected non -
melanoma skin cancer, second SCCHN  tumors , completely  resected minimally 
invasive bladder cancer,  low grade prostate cancer, if Prostate -specific antigen ( PSA) 
≤ 10 ng/mL; non -metastatic localized low grade renal cell carcinoma ( RCC ) or any 
previous (non -synchronous) malignancy if related to germ -line mutations linked to 
either MSI -High (lynch syndrome) or BRCA -1/2 hereditary cance r syndromes, for 
 | Page 13/107

Protocol    14/[ADDRESS_81033] y with study visits/assessments  
 
DLT PERIOD AND 
DEFINITION OF 
DLTS  The DLT period is defined as Cycle 1 *.  
DLT is defined as any of the following treatment -emergent adverse events (TEAEs) which 
are possibly, probably or definitely related to the combination  treatment and  occurring in 
Cycle 1 ( 1 cycle=4 weeks):  
 Any Grade 4 or 5 hematologic toxicity, clinical or laboratory non -hematologic 
toxicity  
 Febrile neutropenia an y grade, Grade 3 thrombocytopenia if associated with bleeding 
or requiring platelet transfusion  
 Grade 2 or higher cardiac or neurologic toxicities, pneumonitis that does not resolve 
within 3 days after starting steroids at adequate doses or that was recurr ent upon 
steroid tapering or withdrawal, myasthenia gravis, myositis, polymyositis, Guillain -
Barre syndrome (excluding peripheral purely -sensory neuropathies)  
 Grade 2 or higher alanine transaminase (ALT)/ aspartate transaminase (AST) 
increase with a concur rent increase of total bilirubin ≥2 x upper limit of normal 
(ULN) and concurrent with alkaline phosphatase (ALP) ≤[ADDRESS_81034] (Hy’s law), in the 
absence of objective causes of biliary obstruction due to obvious disease -related 
causes  
 Any other Grade 3 non -hema tologic, treatment -related clinical toxicity lasting 3 or 
more days despi[INVESTIGATOR_44782], or requiring admission for appropriate 
medical management ; hypersensitivity and/or infusion -related reactions are excluded 
if not reoccurring after appropr iate pre -medication and/or prolonging infusion time  
 Grade 3 non -hematologic laboratory value (excluding lipase, amylase and/or 
autoimmune endocrinopathies manageable by [CONTACT_74296][INVESTIGATOR_014]) if:  
a. Symptomatic and  
b. Medical intervention was promptly required t o treat the patient, or  
c. The abnormality led to hospi[INVESTIGATOR_26109]  
d. The abnormality did not resolve to at least Grade 1 within 2 weeks 
(including the steroid tapering period) despi[INVESTIGATOR_74244]/treatment  
 A delay of >2 weeks due to drug -related toxicity in initiating Cycle 2   
 Unable to complete at least 70% of the scheduled treatment, i.e. , more than six 
Debio 1143 skipped doses in Cycle 1 due to treatment -related toxicity  
 Required dose reduction in Cycle 1 or on Cycle 2 Day 1 or requirement for  treatment 
withdrawal due to treatment -related toxicity (even if not meeting other DLT criteria)  
 
* Any toxicity fulfilling one or more of these criteria but occurring from  C2D1, may be 
defined as delayed DLTs after discussion and agreement between Principal Investigators 
(PIs) , DSMC  and the Sponsor, and may be considered for RP2D definition, if appropriate.  
INVESTIGATIONAL 
MEDICINAL 
PRODUCTS , DOSE 
AND MODE OF 
ADMINISTRATION  Investigational products:  
 Debio 1143 capsules (75 and 100 mg), as bottles of 10 caps ules each, oral route.  
 Nivolumab (OPDIVO®) 10 mg/mL concentrate for solution for infusion, intravenous 
route ( IV). 
Oral Debio 1143 will be administered at a starting dose of 150 mg /d on Days 1 -10 an d Days 
15-24 every four weeks (q4w ). One dose increment of 50 mg (i.e. to 200 mg/d) is planned for 
the subsequent dose level . No dose escalation beyond 200 mg/d is foreseen in this study. In 
individual cases of severe toxicity  or DLT , the Debio 1143 dose will be reduced by a maximum 
of up to two reductions of 50 mg each, and to a minimum dose of 100 mg/d.   
 | Page 14/107

Protocol    15/[ADDRESS_81035] 30 minutes on Days 1 and 15, q4w (i.e., 2 infusions  per 
cycle ). From Cycle [ADDRESS_81036] 60 minutes  on Day 1 exclusively q4w  (i.e., 1 infusion  per cycle ), upon  the 
Investigator ’s request and  Sponsor approval. Neither lower nor higher doses of nivolumab will 
be explored; dose reduction or increase will  not be allowed.  
Infusion of nivolumab will be stopped in case of Grade ≥2 hypersensitivity, inflammatory 
response, or infusion -related reactions. Infusions may be resumed after Grade ≤2 events upon 
resolution of the events within less than 4 hours and af ter medical assessment and agreement 
by a qualified Investigator. Infusion duration will not be shorter than 120  minutes after 
resumption in all subsequent infusions. Treatment will be withdrawn definitively after the 
occurrence of any Grade ≥[ADDRESS_81037] for the medical management of the 
patients under these circumstances.  
Formal premedication is not required . However , premedication m ight be used after C1D1  
administration , if needed  on an individual patient basis, per clinical judgment and local  
institutional  guidelines , as appropriate .  
TREATMENT 
DURATION  Participants are planned to be treated with Debio 1143 and nivolumab for up to 52 weeks (13 
cycles), until any of the following events occurs:  symptomatic PD, asymptomatic but confirmed 
PD (as per iRECIST),  unacceptable toxicity per Investigator judgment and despi[INVESTIGATOR_74245], patient withdrawal, or treatment delay greater than 4 and 8 weeks ( +1 week 
tolerance) for Debio 1143 and nivolumab, respectively.  
Permission to prolong the study treatment for one additional year can be exceptionally  granted 
by [CONTACT_1034], if patients are deriving continuous  clinical benefit from the study treatment. 
Medical justification for extending the treatment and the assessment of the risk/benefit balance 
must be provided  by [CONTACT_74297] . The 
decision to further exten d study  treatment will be re -evaluated on a yearly basis for each patient.  
Re-treatment criteria are listed in Table 2.  
From Cycle 2, i f a patient does not meet the requirements for treatment contin uation on Day 1 
of any cycle, both study drugs will be withh eld until recovery or for a maximum of 4 and 8 
weeks (+1 week tolerance window) for Debio 1143 and nivolumab, respectively. After this 
delay -period, the patient should withdraw from treatment.  
If a patient does not meet the requirements for treatment continuation on any days other than 
D1 (D2 -10 or D15 -24), treatment will be immediately interrupted and the corresponding Debio 
1143 dose (and nivolumab if on D15) will be omitted. Patients should b e re-assessed (ideally 
every 48 -72 hours, if clinically indicated) and treatment will only be resumed after all re -
treatment criteria are met.  
All p atients who withdraw from treatment for any reason will be followed for safety up to 
5 months (± 15 days) af ter the last nivolumab infusion,  complete resolution or stabilization of 
any ongoing toxicity, unless the patient starts a new treatment, end -of-life-care or withdraws 
consent.  
If for any r eason, treatment with nivolumab  is temporarily withheld , Debio 1143  may be 
continued ; however , at any time , and regardless of the reason , if nivolumab is permanently 
discontinued then  Debio [ADDRESS_81038] awn. If for any reason  Debio 1143 is withheld 
temporarily , nivolumab will also be withheld  until treatment may be resumed . Patients will not  
receive any further nivolumab infusion s during the study until  Debio 1143 treatment is 
resumed.    
 | Page 15/107

Protocol    17/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 After PD or start of any new cancer treatment , follow -up for overall survival ( OS) will be 
collected , by [CONTACT_756], email or mail every 4 months  (± 1 month)  until the end of  the Main 
study period .  
There  will be  up to two visits planned for screening and  at least two treatment visits  per cycle  
on D1 and [ADDRESS_81039] one treatment visit from Cycle 4  onwards  if 
applicable , plus one EOT  ± follow -up vis it, as applicable . The total number of onsite visits 
per patient will depend on the total number of cycles delivered which is  based on disease 
progression  status , clinical deterioration, start of new cancer treatments or end-of-life care  or 
death whichever occurs first.  
STUDY VISITS  & 
ASSESSMENTS  Cf. Figure ‘Study plan’ and Table ‘schedule of assessments ’  
STUDY PERIOD  First patient included (FPI): ~ Q1-2019 
Dose optimization part: ~ 3 months  
FPI [INVESTIGATOR_74246]: ~ Q2-2019      
Assessment of the primary clinical endpoint for futility: ~ 6 -9 months after FPI  
[INVESTIGATOR_74247] -futile indications: ~ 3 -9 months (according to results)  
Accrual period: ~ from 9 to 18 months  (depending on futility assessments)  
 End of the Main study period : [ADDRESS_81040] visit 
(LPLV), whichever occurs first   
Extended study period: Only for patients treated beyond 13 cycles. Starts after the Main study 
period and lasts until LPLV.  
End of study ( EOS ): End of Main study period or End of Extended study period , whichever 
occurs last. 
Final  analysis (Final CSR): within 1 year of end of the Main study period. Data collected 
during the Extended study period will be summarized in an addendum to the Final  CSR, after 
the End of Extended study period.    
 
STATISTICAL 
METHODS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sample size  
Part A:  The sample size will be determined by [CONTACT_74298]. Given that (i) a maximum number of two dose levels will be 
explored, (ii) a classical 3+3 design will be used and (iii) at least 6 evaluable patients need to 
be treated at the RP2D before the phase II part starts formally, between 3 -12 evaluable patients 
will be included.  
Part B: Up to 15 evaluable patients will be included in each of the 4 cohorts. In case of no 
early stoppi[INVESTIGATOR_74248], the total sample size will be 60 
patients.  
 
Randomization   
Not applicable  
 
Statistical analysis  
Part A: There will be no formal interim analysis during dose -optimization, only a review of data 
when dose  increase, repeat or reduction is to be decided  at DSMC meetings . The statistical 
analysis of Part A will be mostly descriptive unless otherwise specified.  
Part B: The efficacy of Debio [ADDRESS_81041] v1.1  and/or GCIG  (Cohort 4), 
if applicable . However, for the futility stoppi[INVESTIGATOR_74249]. The 
cut-off for the futility analyses is defined as the time when the last ongoing patient from the first 
8/[ADDRESS_81042]-baseline tumor assessments or prematurely 
discontinued. The nu mber of patients included in the interim analyses and the futility boundaries 
were defined assuming an unconfirmed ORR of 1 7%, a futility response rate of 5%, a maximum 
sample size of 15 patients by [CONTACT_74299] a probability confidence threshold for futility of 20%. 
The futility stoppi[INVESTIGATOR_74250]: [ADDRESS_81043] interim analysis and ≤1 response out of 11 evaluable patients for the second interim 
 | Page 17/107

Protocol    18/[ADDRESS_81044] v1.1 and/or 
GCIG  (Cohort 4 , if applicable ) after the 8th patient is assessed, futility will then be concluded,  
and recruitment will be stopped in the corresponding cohort. If at least one  unconfirmed  
respons e is documented in the first [ADDRESS_81045] 11 evaluable patients, recruitment will continue up t o 15 evaluable 
patients ; otherwise the recruitment will be stopped . For the final efficacy assessment in each 
cohort, first proof of efficacy will be claimed if at least 4 confirmed responses are reported in 
the 15 evaluable patients.  This efficacy boundary was derived assuming a confirmed ORR of 
15% and a probability confidence threshold of efficacy of 80% . 
No formal interim analysis will be performed during the futility monitoring.  Only t he number 
of patients with unconfirmed respons es as per RECIST v1.[ADDRESS_81046] 15% . 
 
In case of homogeneous response rates across the cohorts, efficacy data will be pooled and an 
overall efficacy analysis will be conducted  in addition to the analyses by [CONTACT_9084] . Otherwise , 
efficacy will only be reported by [CONTACT_9084] . All other endpoints such as demographics, baseline 
characteristics, safety, PK, PDy etc. will be presented overall and for each cohort. In case of 
promising efficacy results, f urther confirmatory trials will be then envisaged.  
 
Efficacy analysis  
Efficacy analysis will be conducted in the efficacy and ITT population s (as defined in  section 
11.5.4 ). The main efficacy analysis will be conducted in the efficacy population.  
ORR, immune -related BOR, and DCR will be presented using contingency tables. T ime-to-
response,  DOR , PFS and OS media ns and rates  will be determined using the Kaplan -Meier 
method.  
 
Safety analysis  
Safety analysis will be conducted in the Safety population  (as defined  section 11.5.2 ). 
TEAEs  including those  related to study drugs, TEAEs by [CONTACT_926] (according to the NCI -
CTCAE v5.0 criteria), TEAEs leading to treatment discontinuation and serious adverse events 
(SAEs ) will be summarized by [CONTACT_9313] (SOC) and preferred term (PT) overall and 
by [CONTACT_2715] (Part A) and by [CONTACT_9084] (Part B).  
Data of safety laboratory parameters, vital signs, ECG and ECOG -PS will be presented using 
descriptive statistics. Shift tables and scat ter plots will be provided.  
 
PK analysis  
Plasma/serum concentrations and PK parameters will be presented individually and by 
[CONTACT_9086] . Graphic displays of plasma concentration vs . time curves will be presented 
individually by [CONTACT_74300]. Pharmacokinetic parameters will 
be presented by [CONTACT_74301] ( Part A) and cohort  (Part B) and ov erall as 
descriptive statistics. They will also be derived by [CONTACT_74302] .  
The relationship between PK disposition and clinical response, PDy, safety and genetic 
variations in DMET genes will be analy zed by [CONTACT_74303] . 
These relationships will also be evaluated i n a dedicated Exposure/Response by [CONTACT_74304] 1143 will be pooled. Such 
evaluation will be described in a separate report.  
Pharmacodynamics analysis  
Pharmacodynamics will be presented at baseline and at any scheduled visit with the 
corresponding fold changes (log2) from baseline by [CONTACT_74305]. The maximum 
increase while on-treatment will be similarly presented, along with its fold change from 
 | Page 18/107

Protocol    19/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 baseline.  
Graphics displayin g PDy parameters absolute value s and fold changes from baseline will be 
presented as individual curve and mean (±standard deviation)  curve vs. time.  
Exploratory  analyse s will be conducted to investigate the rela tionship between PDy biomarkers, 
efficacy and safety parameters by [CONTACT_74306].  
 
Pharmacogenetic factor s/predictive biomarker analysis  
Pharmacogenetic factors and predic tive biomarkers assessments will be  exploratory. T he 
correlation between efficacy, pharmacogenetic factors and predi ctive biomarkers will be 
analy zed by [CONTACT_74307].  
 
 
 | Page 19/107

Protocol  21/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
  
*  Examinations should be performed in the following order as applicable: physical examination, vital signs, ECG, safety blood/u rine samples, followed by [CONTACT_74308]/PDy according to specific 
instructions, and othe r examinations: Note: ECGs always have to be taken before PK/PDy sampling.  
 Assessments should be performed on schedule, but occasional changes may be allowed. If the study schedule is shifted, both as sessments and dosing must be shifted to ensure the coll ection of data is 
completed prior to dosing. Windows :  Laboratory assessments and clinical examinations: Screening period: -4 days (i.e., day -32); EOT visit: ±5 days; follow up visits ±1week, in case of holidays, vacations; 
other administrative reasons: ±  [ADDRESS_81047]/MRI assessment = ± 1 week  
#  Assessments for concomitant medications, pregnancy test and AEs will be performed only at the first two FU visits, if applica ble. CT scan or MRI assessments will be performed until confirmed  iRECIST 
PD, symptomatic PD or any new anticancer treatment or end -of-life hospi[INVESTIGATOR_74251].   
µ  Height only collected at screening.  
[ADDRESS_81048] at the following 3 time points: pre -, 0.5-2h Debio [ADDRESS_81049] -dose (before starting the nivolumab infusion or after nivolumab 
perfusion was removed)  and [ADDRESS_81050] -dose ;There should be at least [ADDRESS_81051] be performed before 
PK/PDy sampling. ECG reading will be done centrally and also locally for screening purposes.  
2  Pre-dose (as per section [IP_ADDRESS] ) only required if screening test were performed > 7 days prior to C1D1 or if inclusion/exclusion criteria were not met during screening:   
2a  HIV, HCV and HBV serology testing and CPK and Troponins (I or  T whichever is applicable): Only at screening, to be repeated if clinically indicated only.  
2b  FSH/LH and total testosterone (in male) or estrogens (in female patients), free -cortisol (at morning) and ACTH: Only at screening and to be repeated if clinica lly indicated.  
2c  Hemoglobin, hematocrit, platelets and complete blood cell count and differential counts, creatinine, sodium, potassium, calci um, total bilirubin (if >ULN, then also measure direct bilirubin), ALP, 
AST, ALT,  amylase, lipase, LDH, total protein, albumin, CRP.  
2d Part A patients (only): Total bilirubin (if >ULN, then direct bilirubin should also be measured), ALP, AST, ALT, and creatini ne. 
2e  TSH, FT3 and FT4: At Day 1 and Day 15 in Cycle 1 and every Day 1 of each subsequent cycle.  
2f  CA-125 to be performed at screening within 4 weeks of C1D1, exclusively in applicable patients included in Cohort 4, and to be r epeated before start of each new cycle if abnormally elevated 
before treatment start, unless PD, any new anticancer treatment or end-of-life hospi[INVESTIGATOR_74252].  
3  In women of childbearing potential only: blood test at screening (only required if screening test were performed > 7 days prior to C1D1), then urine dipstick test alone would be sufficient, at the beginning 
of each treatment cycle while on study up to 5 months after EOT.  
4  Every 8 weeks (±1 week) from first on -treatment scan until Cycle 10, then from Cycle 13, every 12 week s (± 1 week) until confirmed iRECIST PD, symptomatic PD or any new anticancer treatment or end -
of-life hospi[INVESTIGATOR_74253], whichever occurs first. For patients who continue study treatment in the Extended study period, tumor response assessments will be 
performed at the frequency of  local institutional care practice until EOT. All patients will have CT or MRI at the time of disease progression, if no ne previously available. CT or MRI done before screening, 
as part of patient’s standard of care and not older than 8 weeks (+1 week tolerance) before C1D1 can be used instead of repeating a new assessment at screening even if done before ICF signature [CONTACT_74367], if deemed clinically appropriate by [CONTACT_737].  
 A contrast enhanced brain CT or MRI is mandatorily at baseline only in SCLC cohort, subsequent brain scans to be done if clin ically indicated.  
[ADDRESS_81052] es will be collected:  
1) An archived biopsy at diagnosis (before prior PD -1/PD -L1 therapy) = optional;  
2) An archived biopsy if collected after prior PD1/PD -L1 or, if not available a fresh biopsy collected at screening will be mandatory;  
3) A fresh biop sy collected at end of Cycle 2 (day 28=Day 1 of the following cycle) = optional  
[ADDRESS_81053] nivolumab ADA will be collected at C13D1 instead of at EOT . 
7  Timepoints as specified in Table 8-4 and windows of tolerance as specified in Table 8-5.   
7a Only at Cycle 6: PGx ctDNA.  
8  Debio 1143 will be taken orally on D1 -10 and D15 -24 on an empty stomach (patients will fast for [ADDRESS_81054] 1 h after dosing) at approximately the same  time each day. Water is 
permitted freely. A missed dose can be taken as soon a s the patient remembers but no later than 6 h after the planned dose. If >[ADDRESS_81055] elapsed, the missed dose should be skipped  and the next dose taken 
according to the regular dosing schedule. A double dose should not be taken to make up for a missed dose. Debio1143 will be  given in the hospi[INVESTIGATOR_307] (before nivolumab infusion whenever is applicable) 
during: Cycle 1 on Days 1,3 (only Part A), 8, 15, 17 (only Part A), 22; Cycle 2 on Days 1 and 15; Cycle 3 on Days 1, 3 (only Part A) , 15, and 17 (only Part A); and  on Days 1 ± [ADDRESS_81056] of the days will be taken at home following relevant medical instructions. A patient’s diary to record treatment com pliance will be provided as a separate document and it will be reconciled with 
the retur ning capsules by [CONTACT_74309].  
[ADDRESS_81057] 30 minutes on Days 1 and 15, every 4 weeks (i.e., 2 infusions in each 
cycle).  
9a  From Cycle 3 on, the switch to an administration of 480 mg of nivolumab only on Day 1 of each 28 -day cycle is allowed based on the Investigator’s judgment and Sponsor’s agreement.  
± Dispensing of nivolumab will depend on the nivolumab schedule administered from Cycle 3 onwards.   
 | Page 21/107

Protocol  22/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 10  Continuous AE monitoring, with Investigator’s assessment and documentation at scheduled study visits up to EOT visit and seco nd follow up visit, if app licable. The SAE reporting period is up to [ADDRESS_81058] nivolumab administration. Patients continuing in follow -up (FU) after EOT, in the first and/or second FU visits will have final AEs update of any ongoing toxicity at this time, if a pplicabl e, 
unless start of new anticancer treatment or end -of-life-care, in which case visit should be scheduled ideally before.  
 11     For Part B, visits on Cycle 1 and Cycle 3 on Days 3 and 17 will not be performed  
12    Including information on current and pre vious tobacco and alcohol use/consumption  
13    Only applicable for patients treated beyond Cycle 13
 | Page 22/107

Protocol  23/[ADDRESS_81059] Service  
CBCDA  Carboplatin  
CD4+ / CD8+  cluster of differentiation 4/[ADDRESS_81060]  DNA damage repair  
DLCO  diffusing capacity of the lungs for carbon monoxide  
DLT  dose limiting toxicity  
DMET  drug metabolism enzymes and transporters  
 | Page 23/107

Protocol  24/[ADDRESS_81061]  
ITT intention -to-treat  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
IV intravenous  
IVIG  intravenous immunoglobulins  
 | Page 24/107

Protocol  25/[ADDRESS_81062]  Response Evaluation Criteria in Solid Tumors  
RP2D  recommended phase II dose  
RT radiotherapy  
SAE  serious adverse event  
SAP statistical analysis plan  
 | Page 25/107

Protocol  26/105 
Debio 1143 -106 
 
 Copyright Debiopharm International  SA 
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 SCCHN  squamous cell  carcinoma of the head and neck  
SCLC  small cell lung cancer  
SD stable disease  
SLE systemic lupus erythematosus  
SMAC  second mitochondrial activator of caspase  
SOC  system organ class  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TEAE  treatment -emergent adverse event  
TIL tumor –infiltrating lymphocyte  
TKI tyrosine kinase inhibitor  
TNFa  tumor necrosis factor alpha  
TSH  thyroid -stimulating hormone  
TTP time to progression  
TXL  paclitaxel  
ULN  upper limit of normal  
[LOCATION_003]N  U.S. Adopted Name  
[CONTACT_74368] -bearing potential  
 
DEFINITION  
IMP “A pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical 
trial, including products already with a marketing authorization but used or assembled (formulated or 
packaged) in a way different from the authori zed form, or when used for an unauthori zed indication, or 
when used to gain further information about the authori zed form.”  
According to the above definition, the Debiopharm International ( DPI) active substance being tested as 
well as associate or comparator drugs used during the study are to be considered as IMPs.  
 | Page 26/107

Protocol    27/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 1. INTRODUCTION  
Immune checkpoint inhibition has resulted in impressive response rates and long -term disease control in 
some cancers and patients. (1, 2) The tumor -derived neo -antigen repertoire plays a key role for im mune T -
cell reactivity and sensitivity to immune checkpoint inhibition with anti -cytotoxic T -lymphocyte antigen -4 
(CTLA -4) and anti -programmed cell death 1/ -ligand 1 (PD -1/PD -L1) therapi[INVESTIGATOR_014]. (3) Patients whose tumor s 
have a high mutation burden (>10 somatic mutations/Mb) and neo -antigen load , such as those with 
melanoma and lung cancer , have been shown to benefit most from immune checkpoint inhibition. (4-6) 
Despi[INVESTIGATOR_74254] -free survival (PFS) a nd overall survival (OS) have been reported 
with immune checkpoint blockade in several advanced malignancies, only 10 -30% of patients respond to 
treatment and most patients  ultimately  develop resistance to therapy. Therefore , strategies to expand the 
exten t and quality of response to immune checkpoint inhibition are required to optimize cancer 
immunotherapy. (7) Combination of immune checkpoint inhibitors  (CPI) with compounds that foster anti -
tumor  immunity and also promote programmed cell death (apoptosis) in tumor  cells may have great 
therapeutic potential  to achieve this goal .(8) 
2. PHARMACEUTICAL AND B ACKGROUND INFORMATIO N  
2.1. Nivo lumab  
Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the PD-[ADDRESS_81063] is activated, inhibiting an 
immune response. By [CONTACT_74310], niv olumab allows the immune system to recognize and 
attack tumor cells. In two pi[INVESTIGATOR_30338] I trials in advanced solid tumor s, nivolumab showed significant 
clinical anti -tumor  activity and was relatively well tolerated at 10 mg/kg once every 2 weeks  (q2w)  as 
monotherapy or in combination with other agents (non -CPIs) .(9, 10) This l ed to several randomized phase 
III trials of nivolumab monotherapy in advanced cancers  including melanoma, non -small cell lung cancer 
(NSCLC), renal cell carcinoma (RCC), classical  Hodgkin lymphoma, squamous cell  carcinoma of the head 
and neck (SCCHN) and others .(11) In the pooled dataset of all patients enrolled in these phase III trials and 
receiving nivolumab 3 -10 mg/kg  q2w as monotherapy across tumor types (n = 2 ,578) with minimum 
follow -up ranging from 2.[ADDRESS_81064] frequent a dverse reactions (≥ 10%) were fatigue (30%), 
rash (17%), pruritus (13%), diarrhea (13%), and nausea (12%). The majority of adverse reactions were mild 
to moderate (Grade 1 or 2). With a minimum of 24 months follow -up in NSCLC, no new safety signals 
were id entified. (12, 13)  
Efficacy of nivolumab  monotherapy  was assessed in a  recent meta -analysis  that included 27 worldwide 
clinical trials  (n=5,551) . The pooled  objective response rate (ORR), the 6 -month PFS and the 1 -year OS 
rates were 26 % (95% confidence interval (CI)  21–31), 40 % (95% CI 34–46) and 52 % (95%  CI: 43–62), 
respectively .(14) In Europe, nivolumab (OPDIVO®) as monotherapy or in combination with ipi[INVESTIGATOR_74255], NSCLC, RCC, classical Hodgkin's 
lymphoma , SCCHN and urothelial carcinoma .  Due to antibod y-specific kinetics, a flat dose was derived 
from the 3 mg/kg  q2w dose by [CONTACT_74311] 80  kg weight, thus b ased on the current 
prescribing information , a nivolumab infusion at either  240 mg (flat dose) q2w or 480  mg every four weeks  
(q4w)  (starting from  Cycle 3)  was identified as the recommended phase II dose (RP2D) . The two treatment 
schedules  are currently being used in daily oncology practice given the extended terminal half -life of IgG4 
antibodies such as nivolumab and the relative lack of potential interactions .(12) It is anticipated that 
switching  the nivolumab schedule  as of  Cycle 3, from D1 , 15 q4w to D1 q4w  with the higher dose , if the 
treating investigator considers this appropriate, is not expected to raise any concerns in regards to efficacy 
or safety , while simplifying treatment administration and hospi[INVESTIGATOR_74256] ’s time constraints and treatment burden to a significant extent.   
 
 | Page 27/107

Protocol    29/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 shown to enhance anti -PD-1 mediated tumor  growth inhi bition by [CONTACT_74312]4 and CD8 T -cells in the tumor .(24)  
A first -in-man study in 31 patients with advanced cancers evaluated short course Debio  1143 monotherapy 
(5-900 mg), given orally once daily on days 1 -5 (q2w or q3w ). Debio 1143 was well tolerated up to the 
maximum dose of 900  mg, with pharmacodynamic (PDy) effects noted at daily doses >80 mg. (25) 
Pharmacokinetics ( PK) studies demonstrated a mean half -life on Day 1 of 5.2 - 7.1 h, regardless of the dose. 
The maximum tolerated dose (MTD) was not rea ched. Common treatment -related adverse events (AE)  that 
occurred with a frequency of >10% included fatigu e (26%), nausea (2 3%), and vomiting (1 3%).(25) While 
gastrointestinal (42%) and skin/subcutaneous (29%) AEs were common, most  drug-related AEs were mild 
to moderate in severity and the frequency and grade of AEs were not dose -dependent. Of the 8 patients 
(26%) with serious adverse events (SAE), none w as considered related to Debio 1143. Four patients (13%) 
discontinued treatment  with Debio 1143 due to AEs ( alanine transaminase [ALT] increase, cranial nerve 
disorder, abdominal pain, dyspnea), with only ALT elevation deemed related to treatment.  
In combination with carboplatin  (CBCDA)  and paclitaxel  (TXL) , short -course Debio 1143 at a dose o f 
200 mg once daily ( Days 1 -5, q3w ) has been determined to be safe and i s the RP2D in combination with 
chemotherapy. (26) Particularly promising results were observed in heavily pre -treated o varian cancer 
patients treated with Debio 1143 in combination with CBCDA and TXL, in which 6 patients out of 18 had 
confirmed partial response (PR) (33.3%).  Extended daily administra tion of Debio 1143 ( Days 1 -14, q3w ) 
of 200 to 400 mg daily dosing has also been reported. (15) The extended schedule was found to have good 
tolerability and a toxicity profile similar to the short -course regimen, with cellular IAP -1 degradation in 
surrogate tissue noted at all doses evaluated. (15) The MTD was not reached up to 400 mg/d and only one 
isolated dose limiting toxicity (DLT) of asymptomatic reversible transaminase elevation was observed at 
200 mg/d, but not at higher doses.  
Extended daily dosing of Debio 1143 is currently be ing evaluated in combination with concurrent chemo -
radiation in patients with locally advanced SCCHN .(27) Debio 114 3 at the dose of 200 mg/d on D ays 1 -14 
every 21 days has been determined to be safe and is the selected RP2D in combination with concurrent 
chemo -radiation. (28) Preliminary findings  showed that 10/14 (71.4%) patients  had complete response (CR) 
and 3 (21.4%) additional patients had PR. Do uble-blind, placebo -controlled, randomi zed phase II trials  
(Debio 1143 -201B and Debio 1143 -203) are ongoing to better address the exact contribution of Debio 1143 
to the efficacy  and safety  of these regimens.   
In addition , a phase Ib/II study  (Debio 1143 -NSCLC -105) of Debio 1143 in combination with avelumab 
(anti-PD-L1) is ongoing in NSCLC patients naïve to CPI. As of 21st of November [ADDRESS_81065] avelumab dose (10 mg/kg on D ays 1 and 15 q4w) (29).The MTD 
was not reached and the RP2D has been defined  as [ADDRESS_81066] been well described in the literature. One NSCLC patient , treated at 150 mg/d Debio [ADDRESS_81067] v1.1 PR at Cycle 6+ as of the cutoff  and 5 stable disease ( SD) were 
observed , providing earl y evidence of clinical activity. Other clinical studies evaluating other CPI 
[INVESTIGATOR_74257] s are planned to assess the immunomodulatory properties of IAP inhibition. (30) 
In summary, a s of July [ADDRESS_81068] cases  as part of a combination containing 
either chemotherapy, chemoradiation or immunotherapy. Debio 1143  was given at a daily dose  ranging 
from 400 -900 mg/d as single agent without the MTD being rea ched. Debio 1143 at  200 mg /d can be safely 
given in combination with carboplatin/paclitaxel, cisplatin, daunorubicin/ cytarabine or with concomitant 
chemo -radiotherapy with cisplatin. In terms of combining Debio [ADDRESS_81069] that 150 mg /d is no n-toxic and 200 
mg/d Debio [ADDRESS_81070] avelumab is  tolerable.  PDy evidence of target occupancy and 
IAP degradation in blood is available from  patients treated at doses as low as 120 mg/d.  
 | Page 29/107

Protocol    30/[ADDRESS_81071] been recognized as two key hallmarks of cancer. A 
dual combination approach that overcomes both of these barriers has been shown in preclinical models to 
effectively eradicate tumor s. Small -molecule IAP a ntagonists, known as SMAC mimetics render cancer 
cells susceptible to cell death and stimulate effector immune cells, resulting in increased anti -tumor  
immunity. (16) The SMAC mimetic Debio 1143 is expected to expand and enhance patients ’ response to 
immune CPIs. 
Immune checkpoint inhibition – in particular monoclonal antibodies targeting PD -1/PD -L1 – is changing 
the treatment paradigm for many cancer types. Pembrolizumab, a PD -[ADDRESS_81072] drug approved 
in oncology which is indicated for the treatment  of tumors with particular molecular feature s, such as 
microsatellite instability -high ( MSI-H) or mismatch repair deficiency ( MMRd ), which cause errors in DNA 
replication resulting in a high mutation load and likely enhanced neoantigen presentation to immu ne cells 
irrespective of their primary tumor origin or location.  Nevertheless, only a limited subset of patients 
responds to single -agent blockade. Combination therapi[INVESTIGATOR_74258]  a mean s of increasing response rates. 
Furthermore, benefit associated with C PI [INVESTIGATOR_74259] .(31, 32) The 
immunogenic properties of the IAP antagonists provide a good rationale for combining Debio 1143 with 
immune CPIs such as nivolumab.  
In a phase III  trial enrolling 423 NSCLC patients with a PD -L1 expression level of 5% or more, nivoluma b, 
as first -line therapy,  was well tolerated with 18 .0% of patients experiencing grade  3/4 treatment -related 
toxicity. Among the 75 patients with follow up >13 weeks, median PFS was 4.2 months and the ORR was 
26.1% (CR: 2%, PR: 24% ), with 38% of patients achieving stable disease (33). 
In clinica l trials, Debio 1143 monotherapy was well tolerated up to a maximum of 900 mg without  reaching 
the MTD with a schedule of Days 1 -5 q2w or q3w . The extended dosing schedule of Debio 1143 (Days 1 -
14 q3w ) also showed good tolerability, with a toxicity profile  similar to the short -course regimen , and the 
MTD not reached with doses up to 400 mg/d. PDy effects were seen with  daily doses >80 mg /d. Treatment -
related AEs (TEAEs) with a frequency of >10% included fatigue (2 6%), nausea (2 3%), and vomiting (1 3%). 
Gastr ointestinal (42%) and skin/subcutaneous (29%) AEs were common, but most drug -related AEs were 
mild to moderate in severity and the frequency and grade of AEs were not dose -dependent. More recently, 
results of a window -of-opportunity trial in patients with SCCHN showed an increased level of tumor -
infiltrating lymphocytes (TILs), especially CD8+ T -cells; as well as increased expression of PD -L1 and 
PD-[ADDRESS_81073]-treatment with Debio 1143 . 
 
  
The combination of immune CPI [INVESTIGATOR_74260] -tumor  immunity and promote 
programmed cell death (apoptosis) in tumor  cells has strong  therapeutic potential and based on their good 
tolerability , the benefit risk balance  is positive .  
A combination of Debio [ADDRESS_81074] of  November 2018 in the Debio 1143 dose 
range explored (100 -250 mg/d) plus the standard avelumab dose showed an acceptable safety profile  
without  any unexpected tox icities . The MTD  was not reached and  the RP2D had been defined at 200 mg/d 
D1-10 and D15 -24 combined with avelumab i.v. at 10 mg/kg on D1 and 15, both  q4w (29). Preliminary 
PK/PD y data f rom this and  other studies  (i.e., Debio 1143 -101/AT -406-C2S-001 and Debio 1143 -202 
Window -of-Opportunity ), show target engagement, adequate tumor distribution and concentrations and 
potential immunomodulatory properties with the 200 mg/d Debio 1143 dose (some already apparent at 80 -
100 mg) . It also has  an acceptable safety profile both as single agent and when combined with a variety of 
other treatments (concomitant chemo -radiotherapy , carboplatin and paclitaxel, cisplatin weekly, etc). Based 
on the known safety profil e of CPI s and SMAC mimetics, and particularly Debio 1143 when given orally 
 | Page 30/107

Protocol    31/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 at 200 mg/d, the risk -benefit ratio for patients treated with the combination as proposed in this study is 
favorable.  See Section 5.3 for the Debio 1143 administration schedule rationale.   
Regarding the risk of drug -drug interactions (DDIs), Debio 1143 is transported by P -glycoprotein (P -gp). 
Accordingly, strong P -gp inhibi tors and inducers are prohibited. In addition, in vitro Debio 1143 
significantly inhibits CYP  3A4/5 and P -gp and has the potential to induce and downregulate CYP 3A4/5, 
2Cs, 2B6, and to downregulate 1A2. The clinical relevance of these phenomena is unknown .  
Accordingly, narrow therapeutic range or sensitive CYP 3A substrates are prohibited. Also, narrow 
therapeutic range or sensitive  substrates of P-gp, CYP 2C s, 2B6 or 1A2 should be closely monitored.  
4. STUDY OBJECTIVES  
4.1. Primary objectives  
4.1.1.  Part A  
The p rimary objective of the dose -optimization  part of the study is to determine the RP2D  taking into 
account DLT/s in Cycle 1, overall  safety/tolerability and PK , by [CONTACT_74292] [ADDRESS_81075] dose,  overall and in each patient  cohort . 
4.2. Secondary objectives  
4.2.1.  Part A  
For the dose -optimization part, secondary objectives are to assess the:  
1. PK disposition of Debio 1143  (including its metabolite  Debio 1143 -MET1 ) and nivolumab when 
administered in combination.  
2. Anti-tumor activity of Debio 1143 in combination with nivolumab in patients with advanced solid 
malignancies .  
 
4.2.2.  Part B  
For the basket trial , secondary objectives are to assess the:  
1. Safety and tolerability of  the RP2D of Debio 1143 when given in combination with nivolumab  in 
patients with advanced solid malignancies .  
2. PK disposition of Debio 1143  (and its metabolite  Debio 1143 -MET1 ) and nivolumab when 
administered in combination . 
 
4.3. Exploratory objectives  
1. To exp lore potential predictive and PDy biomarkers of Debio 1143 and nivolumab when 
administered in combination , in blood and tumor tissue,   
 
  
 | Page 31/107

Protocol    32/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 2. To explore genetic variations in drug metabolism enzyme and transporter (DMET) genes associated 
with differences in the PK disposition of Debio 1143 in combination with nivolumab  
3. To explore  the exposure/response relationship for efficacy and safety (including PK/PDy 
correlations , if applicable) of Debio 1143 in combination with nivolumab  
4. To explore  correlation s between response, clinical parameters, im mune correlates, and putative 
biomarkers,  
5. To explore the relationship between Debio 1143 plasma concentrations and QTcF  
5. STUDY DESIGN AND TRE ATMENT  
5.1. Study design  
This study will be conducted in  two sequential  parts, i.e. , a dose -optimization phase Ib (P art A)  and an 
exploratory phase II basket  (multiple parallel cohorts)  trial ( Part B ), to evaluate  Debio [ADDRESS_81076] dose of nivolumab in patients with advanced /unresectable  solid malignancies who have 
progressed during or immediately after anti -PD1/PD -L1 treatment . 
A Data Safety Monitoring Committee (DSMC) will overview study conduct during both parts A and B. A 
full charter will be provided as a separate document.   
5.1.1.  Part A  
Part A has an  open -label, multicent er dose -optimization  design applying the classical 3+ [ADDRESS_81077] doses of nivolumab (OPDIVO®) to 
determin e the RP2D taking into account safety/tolerability and PK, as well as the treatment compliance in 
pretreated patients with advanced solid malignancies including: small cell lung cancer ( SCLC ); SCCHN; 
MSI-H, MMRd or other DNA damage repair (DDR) abnormalitie s, including homologous recombination 
deficiency (HRD) in gastrointestinal  (GI) cancers; known DNA MMRd/MSI -H, breast cancer (BRCA) -1/2 
hereditary or somatic/ sporadic mutations, or other DDR abnormalities including HRD in platinum -resistant 
ovarian, endom etrial, primary peritoneal or cervical cancers. Patients must have received at least, one prior 
systemic line of standard treatment and must have progressed or relapsed during or immediately after a 
prior anti -programmed cell death -1 (PD -1)/ programmed cell death -ligand 1 (PD -L1) based -treatment, 
given either as a single agent or in combination with standard/approved chemotherapy, tyrosine kinase 
inhibitors (TKIs) or other monoclonal antibodies (mAbs) that are not known to modulate/inhibit immune 
checkpoint s. Patients with p rior cytotoxic T -lymphocyte antigen 4 (CTLA -4) or lymphocyte activation 
gene -3 (LAG -3) combinations with PD -1/PD -L1 are excluded; any other prior combinations with 
checkpoint inhibitors (CPI) should be discussed and agreed by [CONTACT_74291].   
Eligible patients will enter Part A of the study in cohorts of three evaluable patients. The starting dose of 
Debio 1143 will be 150 mg, daily, administered orally for 10 consecutive days ever y 2 weeks (i.e., Days 1 -
10 and D ays 1 5-24 inclusively of each 28 -day cycle  [q4w]). The d ose will be optimized according to the 
observed DLTs, patient treatment compliance, safety/ tolerability and PK data, if applicable.  
The DLT period is defined as Cycle 1  (i.e. lasting 4 weeks or longer in case of dosing delays) . Treatment -
related toxicities fulfilling DLT criteria but occurring after Cycle 1 (i.e., delayed DLTs) may also be 
considered for RP2D definition after discussion and agreement between the Investigators , DSMC and the 
Sponsor.  
Nivolu mab will be administered at 240 mg (flat dose) over at least [ADDRESS_81078] with the Sponsor agreement.  
The maximum explored Debio 1143 dose will be 200 mg/d . Neither Debio 1143 dose escalation beyond 
this threshold nor any nivolumab dose increases are foreseen in this study. In individual cases of severe 
 | Page 32/107

Protocol    33/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 toxicity, the Debio 1143 dose may be reduced by a maximum of two decrements of 50 mg/d or up to a 
minimum dose of 100 mg/d.   
According to the 3+[ADDRESS_81079] 3 
patients experiences a DLT  during Cycle 1 , 3 more patients will be treated at the same dose level. If ≤ [ADDRESS_81080] cycle , at the starting dose level, dose escalation 
will then proceed to the second dose level. If ≥ [ADDRESS_81081] been clarified. If the dose is increased to the second dose 
level, 3 to 6 evaluable patients will be included and the 3+3 design rules will be applied again. If ≤ [ADDRESS_81082] cycle at the second dose level , this dose will be 
considered the optimal dose level . If ≥ [ADDRESS_81083] 
cycle at the second dose level, the initia l dose level will then be declared the optimal dose, given that < 
33% of evaluable patients have experienced a DLT during the first cycle and there are at least [ADDRESS_81084] 6 evaluable patients shoul d be treated at the RP2D before Part B o f the study may start. Once the 
RP2D  is defined, any patient still receiving treatment can  be switched  to the RP2D, if deemed appropriate 
by [CONTACT_74313] . 
 
5.1.2.  Part B  
Part B is  a multicent er, open -label , basket trial using Debio 1143  in combination with nivolumab at the  
RP2D  as previously defined in Part A, in patients with advanced/unresectable solid tumors. Eligible patients 
will be simultaneously included into four cohorts according to tumor type :  
 Cohort 1 : SCLC  (including extrapulmonary small -cell carcinomas or large cell neuroendocrine 
lung carcinoma, as per WHO Classification of Lung Tumors of 2015  (34) 
 Cohort 2 : SCCHN  (nasopharyngeal carcinomas are excluded)  
 Cohort 3 : GI cancers, including esophageal, gastric, colorectal or pancreatobiliary tumors, with 
known MSI -H/ MMRd or other known DDRs abnormalities (incl . HRD).  
 Cohort 4 : platinum -resistant EOC), endometrial cancer, PPC and cervical cancer, with known 
MSI-H/ MMRd, hereditary/somatic mutations of the BRCA1 and BRCA2 genes or other  known  
DNA DDRs abnormalities (incl. HRD).  
The primary objective of Part B i s to assess whether the combination of Debio 1143 with nivolumab is 
active overall  and in each cohort. Early futility stoppi[INVESTIGATOR_74261]  (unconfirmed) will be used. 
In each cohort, if no unconfirmed response is observed according to Response Evaluation Criteria in Solid 
Tumors (RECIST v1.1)  or Gynecologic Cancer Intergroup ( GCIG ) criteria  (Cohort 4 , if applicable ) once 
the initial [ADDRESS_81085] one 
response (unconfirmed) is documented in the initial [ADDRESS_81086] 15% . If homogeneous response rates are seen across the cohorts, efficacy data will be pooled and an 
overall efficacy analysis will be conducted  in addition to the analyses by [CONTACT_9084] . For the final efficacy 
assessment , first proof of efficacy will be claimed in a given cohort if at least 4 confirmed objective 
responses are reported in the 15 evaluable patients.  
 | Page 33/107

Protocol    34/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 In the case of insufficient accrual in any cohort (e.g. less than 2 patients in 6 months)  despi[INVESTIGATOR_74262], enrolment may be stopped in that cohort.  
During part B the DSMC  will meet  approximately  every 3 months, and more frequently if needed in the 
event of  rapid recruitment. A charter will be provided separately.  
5.2. DLT period and definition of DLTs   
The DLT period is defined as Cycle 1 *. 
DLT is defined as any of the following treatment -emergent adverse events (TEAEs) which are possibly, 
probably or definitely related to the combination  treatment and  occurring in Cycle 1  (1 cycle=4 weeks):  
 
 Any Grade 4  or 5 hematologic toxicity, clinical or laboratory non -hematologic toxicity  
 Febrile neutropenia any grade, Grade 3 thrombocytopenia if associated with bleeding or requiring 
platelet transfusion  
 Grade 2 or higher cardiac or neurologic toxicities, pneumonitis that does not resolve within 3 days 
after starting steroids at adequate doses or that was recurrent upon steroid tapering or withdrawal, 
myasthenia gravis, myositis, polymyositis, Guillain -Barre syndrome (excluding peripheral purely -
sensory neuropathies)  
 Grade 2 or higher alanine transaminase (ALT)/ aspartate transaminase (AST) increase with a 
concurrent increase of total bilirubin ≥2 x upper limit of normal (ULN) and concurrent with alkaline 
phosphatase (ALP) ≤[ADDRESS_81087] (Hy’s law), in the absence of objective causes of biliary obstruction 
due to obvious disease -related causes  
 Any other Grade 3 non -hematologic, treatment -related clinical toxicity lasting 3 or more days 
despi[INVESTIGATOR_74263] c are, or requiring admission for appropriate medical management ; 
hypersensitivity and/or infusion -related reactions are excluded if not reoccurring after appropriate 
pre-medication and/or prolonging infusion time  
 Grade 3 non -hematologic laboratory value (ex cluding lipase, amylase and/or autoimmune 
endocrinopathies manageable by [CONTACT_74296][INVESTIGATOR_014]) if:  
a. Symptomatic and  
b. Medical intervention was promptly required to treat the patient, or  
c. The abnormality led to hospi[INVESTIGATOR_26109]  
d. The abnormality did not resolv e to at least Grade 1 within 2 weeks (including the steroid 
tapering period) despi[INVESTIGATOR_74264]/treatment  
 A delay of > 2 weeks due to drug -related toxicity in initiating Cycle 2   
 Unable to complete at least 70% of the scheduled treatmen t, i.e. more than six Debio 1143 skipped 
doses in Cycle 1 due to treatment -related toxicity  
 Required dose reduction in Cycle 1 or on Cycle 2 Day 1 or requirement for  treatment withdrawal 
due to treatment -related toxicity (even if not meeting other DLT criteria)  
*Any toxicity fulfilling one or more of these criteria but occurring from  C2D1, may be defined as delayed 
DLTs after discussion and agreement between principal  Investigators (PIs) and the Sponsor, and may be 
considered for RP2D definition, if appropriate.  
5.3. Study treatments  
Debio 1143: rational e for dose regimen  
Since Debio [ADDRESS_81088] treatment used in the combination.  
A 10-day on / 4-days off schedule given every 2 weeks  (i.e., repeated twice in a 4 -week cycle)  of Debio 
[ADDRESS_81089]  nivolumab . This schedule is 
being tested in an ongoing Debio 1143 -NSCLC -105 study in combination with avelumab  ([STUDY_ID_REMOVED]) . 
The 4-day wash -out period allow s recovery from potential Debio 1143 -related toxicity  and gives a lower  
 | Page 34/107

Protocol    38/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 tolerance). D uring this period, patients may continue to re ceive Debio 1143 as per protocol, if appropriate . 
Patients requiring more than 8 weeks ( ±1 week) of nivolumab interruption and those who permanent ly 
discontinue nivolumab  for any reason , will discontinue Debio 1143 permanently and will be withdrawn 
from the study . The n ivolumab dose will not be adjusted under any circumstances.  
Patients experiencing any treatment -related grade 4 toxicity (clinically or laboratory, excludin g grade 4 
amylases and/or lipase and/or non -febrile neutropenia) will withdraw from treatment definitively without 
further reduction (see section [IP_ADDRESS]  for details) .  
Patients experiencing any  other  treatment -related toxicity fulfilling applicable DLT criteria (as shown 
below) at any time during the study must stop treatment and may only res ume treatment after adequate 
recovery  to re-treatment criteria .  
Treatment must be re -started with a Debio [ADDRESS_81090] up to two 
dose adjustments of 50 mg/d (each one) up to a minimum dose of 100 mg/d Debio 1143  (i.e. 1st dose 
reduction 150 mg/d, 2nd dose reduction 100 mg/day) . Patients still requiring a dose adjustment with a  dose 
of 100 mg/d will be withdrawn from  the study. Once adjusted, Debio [ADDRESS_81091] be implemented in the event of any of the following:  
 Any Debio 1143 -related  Grade 4 hematologic toxicity  
 Debio 1143 -related f ebrile neutropenia any grade, or Grade 3 thrombocytopenia if associated with 
bleeding or requiring platele t transfusion  
 Debio 1143 -related gr ade 2 or higher alanine transaminase (ALT)/ aspartate transaminase (AST) 
increase with a concurrent increase of total bilirubin ≥2 x upper limit of normal (ULN) and 
concurrent with alkaline phosphatase (ALP) ≤[ADDRESS_81092] (Hy’ s law), in the absence of objective 
causes of biliary obstruction due to obvious disease -related causes  
 Any Grade 3, treatment -related , non -hematologic  clinical toxicity lasting 3 or more days despi[INVESTIGATOR_74265], or requiring admission for appropriate medical management; 
hypersensitivity and/or infusion -related reactions are excluded if not reoccurring after appropriate 
pre-medication and/or  prolonging infusion time  
 Grade 3 non -hematologic laboratory value (excluding lipase, amylase and/or autoimmune 
endocrinopathies managea ble by [CONTACT_74296][INVESTIGATOR_014])  
 A delay of >2 weeks due to drug -related toxicity in initiating subsequent c ycles, or a second delay 
lasting >24 h but <2 weeks   
 Unable to complete at least 70% of the scheduled treatment, i.e. more than six Debio 1143 skipped 
doses during any cycle  due to treatment -related toxicity or more than 2 treatment interruptions  >24 
h but <6 days 
If for any reason Debio 1143 is withheld temporarily, nivolumab will also be withheld until treatment may 
be resumed . Patients discontinuing Debio 1143 definitively for any reason will also discontinue nivolumab 
study treatment.  
Patients requiring no more than 1 treatment interruption  per cycle and for not more than 3 consecutive days, 
may resume treatment without dose adjustments. Patients requiring one interruption greater than 3 days, or 
more than one interruption during any given cycle, may resume treatment only after full recovery and  
adjustment of Debio 1143 dose upon  the S ponsor ’s agreement  (if applicable) . 
Patients interrupting treatment or delaying the start of a new cycle due to any Grade 3 treatment -related 
toxicity will resume treatment after Debio 1143 adjustment ( except G rade 3 neutropenia, 
thrombocytopenia, non -optimally treated fatigue, diarrhea, or nausea). Patients experiencing any Grade 4 
treatment -related toxi city will immediately stop treatment  without any possible  therapy  resumption.  
Omitted Debio 1143 doses will not be re -administered under any circumstances.  Every new cycle  D1 will 
start with the Debio 1143 dose. In case of any cycle delays (D ay 1 delayed greater than 72 hours) , all 
 | Page 38/107

Protocol    39/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 subsequent  doses will be administered according  to the new planning , if feasible (i.e. D ay 1-10 followed 
by D ay 11-14 pause) .  
6. STUDY POPULATION  
All patients included in the study must have selected advanced/unresectable or metastatic solid tumors, and 
must have received at least one prior systemic line of standard treatment and have progressed or relapsed 
during or immediately after a prior anti -PD-1/PD -L1-based  treatment, given either as a single agent or in 
combination with standard/approved chemother apy, TKIs or other mAbs that are not known to 
modulate/inhibit immune checkpoints. P atients with p rior CTLA -4 or LAG -3 combinations with PD -1/PD -
L1 are excluded; any other  prior  CPI [INVESTIGATOR_74266].  
In Part A:  
 Between 3 and 12 evaluable patients are planned.  
 Non-evaluable patients will be replaced , as appropriate . 
In Part B:  
 Cohort 1 : SCLC  (including extrapulmonary small -cell carcinomas or large cell neuroendocrine 
lung carcinoma, as per WHO Classification of Lung Tumors of 2015  (34) 
 Cohort 2:  SCCHN  (nasopharynge al carcinomas are excluded ) 
 Cohort 3:  GI cancers (including esophageal, gastric,  colorectal or pancreatobiliary) with known 
MSI-H/MMRd or other DDR abnormalities, including HRD.  
 Cohort 4:  platinum -resistant EOC, endometrial cancer, PPC or cervical cancer,  with known MSI -
H/ MMRd, hereditary/somatic mutations of the BRCA1 and BRCA2 gen es or other DNA DDR 
abnormalities (incl. HRD).  
 Between 32 evaluable patients (if all cohorts are futile) and 60 evaluable patients (if none of the 4 
cohorts is futile) (see section 11.1 for details on sample size).  
 Non-evaluable patients will be replaced.  
6.1. Inclusion criteria  
The same tumor types are eligible in Part A an d B. 
 
All patients must  fulfil all the following criteria (both Parts A and B, unless specified otherwise):  
1. Willing and able to sign a written informed consent form;  
2. Male or female ≥18 years of age.  
3. Histologically and/or cytologically confirmed advanced/ unresectable  or metastatic solid tumor for 
one the following indications:  
a. SCLC  
b. SCCHN  (except nasopharyngeal carcinoma)  
c. GI cancers, including esophageal, gastric, colorectal or pancreatobiliary with known MSI -H/MMRd 
or any other known DDRs abnormalities, in cluding HRD  
d. Platinum -resistant* EOC, endometrial cancer, PPC or cervical cancer, with known MSI -H/ MMRd, 
hereditary/somatic mutations of the BRCA1 and BRCA2 genes or other known DNA DDRs 
abnormalities (incl. HRD)  
* Platinum -resistant is defined as relaps e or progressive disease (PD) occurring within 1 to 6 months 
(180 days) after a platinum -containing chemotherapy.  
4. Have received at least one prior line of standard systemic chemotherapy in the 
advanced/unresectable cancer setting (standard adjuvant/neoadj uvant treatment is acceptable if 
 | Page 39/107

Protocol    40/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 relapse occurred within six months of treatment end) and have no established standard therapeutic 
alternatives.  
5. Have progressed or relapsed during or after a prior anti -programmed cell death -1 (PD -1)/ 
programmed cell death -ligand 1 (PD -L1)-based  treatment, given either as a single agent or in 
combination with standard/approved chemotherapy, tyrosine kinase inhibitors (TKIs), radiotherapy  
(RT) or other monoclonal antibodies (mAbs) that are not known to modulate/inhibit immune 
checkpoints (CPIs)  
6. Minimum washout periods since prior therapy until treatment start (C1D1) (in case s of more than 
one prior treatment type, whichever has the longest mini mum period applies):  
a. 3 weeks for chemotherapy (6 weeks, specifically for nitros oureas or mitomycin C 
containing regimens);  
b. 4 weeks for any prior mAbs or live vaccines ; for any investigational mAbs  [ADDRESS_81093]    
c. 3 weeks for prior RT (1 week in case of localized antalgic/hemost atic hypofractionated RT 
flash)   
d. 2 weeks for TKIs, hormonal therapy, other anti -cancer treatment not previously specified 
or investigational agents  
e. 4 weeks for any maj or surgery  
f. Immunosuppressive medication: within 2 weeks, with the exception of intranasal and 
inhaled corticosteroids or systemic corticosteroids at physiological/replacement doses, 
which should never exceed 10 mg/d prednisone, or an equivalent corticoster oid 
7. Measurable disease (Part B  only) according to RECIST v1.1 or GCIG  criteria in Cohort #4 (if 
applicable) and documented PD during or after  prior PD -1/PD -L1 based therapy  
8. ECOG Performance Status  = 0 or 1   
9. Adequate hematologic renal and hepatic function:  
a. absolute neutrophil count (ANC) ≥  1.5 x109/L,  
b. platelets ≥  100 x109/L,  
c. hemoglobin ≥ 9.0 g/dL,  
d. AST and ALT ≤ [ADDRESS_81094]  (≤ 5x ULN if liver metastases are present) , 
e. total bilirubin ≤ 1.[ADDRESS_81095],   
f. serum creatinine ≤ 1.[ADDRESS_81096],  
g. serum albumin ≥ 30 g/L  
10. Available archived tumor samples for biomarker analysis obtained after prior PD -1/PD -L1 
treatment failure or, if no archived tumor sample is available, patient must be suitable and willing 
to undergo a percutaneous or endoscopic biopsy without unacceptable major ris ks before starting 
study treatment . 
11. Participants with known central nervous system (CNS) and/or meningeal involvement will be 
eligible if they are clinically asymptomatic, have completed primary CNS therapy more than 4 
weeks before treatment start (such as  whole brain RT, stereotactic radiosurgery, or complete 
surgical resection),  and have remained off steroids (including tapering doses) for at least 2 weeks  
12. Women of child -bearing potential  (WOCBP) : 
a. Negative serum pregnancy test at screening;  
b. Agreement to u se highly effective contraception methods from study entry and for up to [ADDRESS_81097] day of study treatment  
6.2. Exclusion criteria  
Any of the following would render a patient ineligible for inclusion  (in both Parts A and B, unless specified 
otherwise):  
 | Page 40/107

Protocol    41/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 1. Thoracic or head and neck rad iation >30 Gy within the 6 weeks prior to C1D1 ; 
2. Have received , in total,  more than 3  (i.e. Cohorts 1&2) or 4 (i.e. Cohorts 3&4)  lines of prior systemic 
treatments (including adjuvant or neoadjuvant regimens if relapse within six months  prior to C1D 1); 
3. Active moderate alcohol consumption, at screening, more than 100/140 grams (3.5/4.9 ounces) of 
alcohol per week for female and male patients, respectively  
4. Liver cirrhosis Child -Pugh score B or C  
5. Prior treatment with an anti -CTLA -4 or anti -LAG3 in combination with PD -1/ PD -L1 CPI, unless 
discussed and agreed with the Sponsor  
6. Prior treatment with SMAC mimetics  
7. Prior PD -1/PD -L1 discontinuation due to severe immune -related toxicity, not resolved upon adequate 
stero ids/immunosuppressive treatment  
8. Requir ement of concomitant treatment with any prohibited medication (See  Appendix B: Prohibited 
medications  and special warnings ) 
9. Ongoing toxicity from prio r administration of any other investigational drug and/or anti -cancer 
treatment of > Grade 1 NCI-CTCAE v5.0 before treatment start  (except for grade 2 alopecia , stable 
sensory neuropathy,  vitiligo or any endocrinopathy adequately managed by [CONTACT_74314])  
10. Patient s with known history of:  
a. Uncontrolled or symptomatic angina or myocardial infarction, within the last 12 months  prior 
to C1D1   
b. Elevated (>ULN) troponin s (T or I) or  creatine phosphokinase  (CPK ) > 1.5xULN  during 
screening  
c. Symptomati c intestinal sub -occlusion  
d. Infection, active or latent by [CONTACT_74294] (HIV), hepatitis B virus (HBV) 
and hepatitis C virus (HCV)  
e. Ongoing arrhythmias requiring treatment, including asymptomatic QTc interval as correcte d 
by [CONTACT_6550] (F) >4 80 msec  
f. In patients previously treated with anthracycline -containing chemotherapy or thoracic RT, non -
adequate cardiac function with left ventricular ejection fraction (LVEF) <50%, measured by [CONTACT_74315] (ECHO) or a multigated acquisition (MUGA) as per institutional standards  
g. Active rheumatoid arthritis, active inflammatory bowel disease (IBD), primary sclerosing 
cholangitis, autoimmune hepatitis, systemic lupus erythematous (SLE), multiple sclerosis or 
any other ongoing autoimmune disease requiring systemic treatment (excluding vitiligo, mild 
cutaneous psoriasis and asymptomatic autoimmune endocrinopathy well controlled under 
hormonal replacement therapy)  
h. Evidence of active, non –infectious pneumonitis or a history of interstitial lung disease  
i. Active ongoing infection requiring systemic antibiotic therapy, including active tuberculosis  
11. Evidence or clinical suspi[INVESTIGATOR_74243] (RBC) transfusions 
within [ADDRESS_81098] 
1 year prior to C1D1 , except: completely rese cted non -melanoma skin cancer, second SCCHN  tumors , 
completely resected minimally invasive bladder cancer, completely resect ed ≤ pT1N0 invasive breast 
cancer , low grade prostate cancer if PSA ≤ 10 ng/mL, non -metastatic localized low grade RCC or any 
previo us (non -synchronous) malignancy if related to germ -line mutations linked to either MSI -High - 
(lynch syndrome) or BRCA -1/[ADDRESS_81099] y with study visits/assessments  
 | Page 41/107

Protocol    42/[ADDRESS_81100] 70% of Debio 1143  (i.e., a maximum of 6 missed 
Debio 1143 doses) and at least one nivolumab dose as planned in  Cycle 1 and were evaluated for DLT or if 
the patient discontinued treatment earl y due to any toxicity that could be considered a DLT.  
Non-evaluable patients  will be replaced , as appropriate (see section 11.5.1 ).  
Part B  
Patients will be evaluable for efficacy if the following two conditions are met:  
o Measurable disease at baseline as per RECIST v1.1 and/or GCIG criteria (Cohort 4 , if applicable ), 
o At least one efficacy assessment, either computed tomography (CT) or magnetic resonance imaging 
(MRI) for RECIST evaluable patients , or CA -125 dosage performed after baseline, if applicable , 
or treatment discontinuation occurred before the efficacy assessmen t was done due to treatment 
failure, defined as any of the following: death, unacceptable toxicity, clinical deterioration and/or 
symptoms worsening . 
Non-evaluable patients will be replaced.  
7. CLINICAL SUPPLIES  
7.1. Investigational medicinal products  
7.1.1.  Debio [ADDRESS_81101] gelatin capsules (75 mg yellow, 100 mg white 
opaque) containing API [INVESTIGATOR_74267], for oral administration.  
7.1.2.  Nivolumab  
Commercially available n ivolumab (Op divo®) will be pr ovided by [CONTACT_941] S ponsor.  
7.2. Packaging and storage of IMPs  
Packaging and labeling will be in accordance with applicable local regulatory requirements and applicable 
Good Manufacturing Practice (GMP) guidelines.  
7.2.1.  Packaging  
Debio [ADDRESS_81102] gelatin capsules will be packed in opaque high density polyethylene bottles with a sealed 
child -resistant closure. Each bottle will contain 10 capsules of either 75 mg yellow capsules or 100 mg 
white capsules.  
Nivolumab (Opdivo®) commercia l presentations , 1 x 4 mL vials , 1 x 10 mL vials  and/or [ADDRESS_81103] a white one. Commercial pack Nivolumab (Opdivo®) will be overlabelled to dispense study related 
information as appropriate per local regulations, storage conditions and expi[INVESTIGATOR_74268]. 
Label text will comply with local health authority requ irements in each participating country.  
 | Page 42/107

Protocol    43/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 7.2.3.  Storage  
Debio  1143 capsules should be stored at a controlled temperature of 15-25°C, protected from direct heat 
and contact [CONTACT_50641] . It will  be shipped and dispensed at ambient temperature. Do not freeze.  
Nivo lumab must be shipped and stored at 2 -8°C until use. Do not freeze.  
7.3. Dispensing and accountability of IMPs  
The IMPs and certificates of an alysis will be provided to the I nvestigators by [CONTACT_74316], who will also ensure relea se of the IMPs as per current GMP  guidelines. Any documentation 
required by [CONTACT_74317].  
The I nvestigator/pharmacist at each study site will inventory and acknowledge receipt of all IMP sh ipments. 
The IMPs accompanied by [CONTACT_74318], must be kept in a locked area with access 
restricted to designated study personnel, and must be stored in accordance with the manufacturer's 
instructions.  
The Investigator/pharmacist at  each study site will keep accurate records of the IMP (and other study -related 
drugs) dispensed. These records will specify dates and amounts dispensed, to and by [CONTACT_20898] (drug 
dispensing list), and report any IMPs accidentally or deliberately destroyed.  
Each dispensing of study drug will be documented by [CONTACT_74319] ’s number, and date dispensed 
on the Drug Accountability Form in the e lectronic case report form (e CRF )/electronic data capture ( EDC ) 
system.  
At study closure, unused IMPs will be counte d and returned to the S ponsor  or destroyed with their written 
permission. Any discrepancies between the IMPs returned and the expected balance must be justified.  
Unused IMPs must not be discarded or used for any purpose other than the present st udy. Throug hout the 
study, the S ponsor ’s monitor/representative will collect the drug accountability forms along with any 
unused IMPs in the original packaging.  
  
7.4. Patient numbering  
7.4.1.  Screening number  
During the screening period (between Day –28 to –1), each potential study  patient will be identified by a 
unique screening number which is displayed when the patient is first recorded in the eCRF  via the internet -
based application. The screening number allows the patient ’s data to be entered into the eCRF and 
subsequently ensures an expedited process when s/he is ready to start the study.  
The Screening # consists of a unique [ADDRESS_81104] at the cen ter (starting at 001). Screening 
#106001, for example, identifies the first subject (001) screened at study cent er 106. The second subject 
screened at the same study cent er will be given Screening # 106002, etc.  
If a screened patient fulfils all eligibilit y criteria and none of the exclusion criteria, the Investigator or 
designated study coordinator will request enrollment of the patient via the eCRF on study Day 1. Enrollment 
should not be requested before the patient is fully eligible and ready to start t reatment.  
7.5. Blinding and unblinding methods  
Not applicable, as this is an open -label study.  
 | Page 43/107

Protocol    44/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 7.6. Method of administration and compliance  
7.6.1.  Debio 1143  
Debio 1143 capsules are ready to use and will be taken orally once daily for 10  consecutive days every 
2 weeks of a  28-day cycle (Days 1 to 10 and Days 15 to 24 q4w).   
Patients should fast [ADDRESS_81105].  
Patients ’ compliance will be verified on Day [ADDRESS_81106] visua l supervision at dosing 
by [CONTACT_941] I nvestigator or his/her designee when administered at the hospi[INVESTIGATOR_307] , or by [CONTACT_3553] a diary card to be 
filled out after each dose when taken at home (the number of capsules, date and time of dosing will be 
recorded). The dia ry card will be checked by [CONTACT_941] I nvestigator or his/her designee at each study visit.  Any 
change in the daily dosing of Debio 1143, must be appropriately reflected in the patient ’s diary by [CONTACT_74320]/her designee, such as dose reduction, dose omissions, and t reatment resumption, as 
applicable.   
7.6.2.  Nivo lumab  
[IP_ADDRESS].  Pre-infusion procedures  
Nivolumab will be administered at 240 mg (flat dose) as an IV infusion , over at least 30 min , on D1 and 
D15 q4w (1 cycle =4 weeks and two infusions ) or [ADDRESS_81107] 60 min, on D1 q4w (1 cycle=4 weeks 
and one infusion)  from Cycle 3 . 
For instructions on preparation of nivolumab infusion, please refer to locally approved labelling.  
A preparation manual will describe in detail  the infusion bags and m edical devices to be used for the 
preparation of the dilution and subsequent administration.  
Formal premedication is not required. However , premedication might be used after C 1D1 administration , 
if needed,  on an individual patient basis, per clinical judgment and local institutional guidelines, as 
appropriate .  
[IP_ADDRESS].  Peri- and post -infusion procedures  
For the infusion, p atients must be observed  according to standard applicable institutional guidelines, if 
applicable, o r for approximately  [ADDRESS_81108] be assured.  
Infusion of nivolumab will be stopped in case of G rade ≥2 hypersensitivity, inflammatory response, or 
infusion -related reactions. Infusions may  be resumed after G rade ≤2 events upon resolution of the events 
within less than 4 hours and after medical assessment and agreement by a qualified Investigator. Infusion 
duration will not be shorter tha n 120 minutes after resumption in all subsequent infusions.  
 | Page 44/107

Protocol    55/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 7.7. Concomitant therapy  
Administration of concomitant medications /therapi[INVESTIGATOR_74269] m edications page of the eCRF. A medication or therapy is defined as concomitant when 
administered between the date of signature [CONTACT_74369] ( EOS ). Information to be 
reported on the eCRF includes: i) international non -proprietary nam e and trade name, ii) dosage information 
(dose, unit, frequency, route), iii)  dates of administration, and iv) reasons for use.  
7.7.1.  Permitted medications  
Permitted medications are:  
 Supportive therapi[INVESTIGATOR_74270], nausea, vomiting, and diarrhea  (per the Investigator ’s decision) . 
 Granulocyte colony -stimulating factor (G -CSF) and erythropo ietic agents (per the Investigator ’s 
decision) . 
 Transfusions and blood -derived products as per local institutional guidelines.  
 Bisphosphonates or denosumab as per local institutional guidelines in patients with symptomatic 
bone metastases, or malignant hypercalcemia or with increased risk of bone fractures.  
 Steroids or anti -histaminic drugs  according to  local institutional  standard protocols  or guidelines  (if 
any) for allergic reactions Grade ≥2 or prophylactically after C 1D1.  
 Patients requiring prolonged systemic steroids administration for any emerging medical cause at 
doses in excess of physiological r eplacement doses or more than prednisone 10 mg/d, should  
discontinue study treatment according to risk/benefit evaluation.  
 Levetiracetam and pregabalin (per the Investigator ’s decision) .  
 Treatment of pain should be done according to severity and recommen ded drugs. Study -specific 
guidelines will be available.  
 Any other medication for the well -being of the patient except those mentioned as  prohibited 
medications at the I nvestigator ’s discretion.   
 The use of oral contraceptives should be carefully evaluated during study treatment as well as the 
use of other drugs reported to cause liver injury.  
7.7.2.  Prohibited medications  
Attention should be paid to treatment that could influence the intended effects or mask side effects of study 
treatment. Use of drugs reported to cause liver injury should be carefully evaluated.  
Concomitant use (until the EOT visit) of the following drugs and treatment modalities is prohibited  (see 
Appendix B: Prohibited medications  for the full list ), except if they are indicated to treat a ny TEAEs related 
to study treatment  ([i.e. anti -TNF -α therapy ]). In th is case, administration  of these drugs  is allowed and 
must be documented after interrupting Debio 1143 treatment .  
 Strong P -gp inhibitors or inducers  (see Appendix B: Prohibited medications ) 
 Anti-TNF -α therapy (e.g, adalimumab [H umera®], etanercept [Enbrel®], infliximab [Remicade®], 
etc.)  
 Other investigational agents other than mAbs within a 2-week period prior to  initial dosing or while 
receiving Debio  1143  
 Systemic c orticosteroids, exceeding 10 mg/d of prednisolone or equivalent or physiological 
replacement doses of hydrocortisone.  Note:  topi[INVESTIGATOR_74271], megestrol, or 
inhaled corticosteroids for reactive airway disease are permitted . 
 | Page 55/107

Protocol    56/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
  Alcohol dependency defined as drinking greater than 100/14 0g (3.5/4.9 ounces) of alcohol per week 
for female /male patients, respectively    
 Grapefruit juice or grapefruit -containing products and St John ’s Wort containing products  
 Narrow therapeutic range or sensitive CYP 3A substrates or other drugs on the prohibi ted medication 
list (see Appendix B: Prohibited medications ). 
 
Restrictions also apply for P -gp substrates during Debio 1143 on -treatment periods (see Appendix B: 
Prohibited medications ). In addition, narrow therapeutic range or sensitive CYP 2Cs (2C8, 2C9, 2C19), 
2B6 or 1A2 substrates should be clos ely monitored. A list of drugs that are sensitive substrates of CYPs is 
available from website resources such as: Flockhart DA. Drug Interactions: Cytochrome P450 Drug 
Interaction Table. Indiana University School of Medicine (2007); 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx . 
Finally, considering that the potential of Debio 1143 to prolong the QTc interval has not yet been fully 
characterized, caution should be exercised when using  Debio 1143 with drugs having a known risk of QTc 
prolongation (refer to product label or Arizona CERT database at website: http://www.crediblemeds.org). 
Monitoring of patients ’ electrolyte levels is strongly recommended.  
7.7.3.  Contraceptive measures  
Based on its mechanism of action and data from animal studies, i t is known that  nivolumab can cause fetal 
harm when administered to a pregnant woman. In animal reproduction studies, administration of nivolumab 
to cynomolgus monkeys from the onset of organogenesis t hrough delivery resulted in increased abortion 
and premature infant death. Human IgG4  is known to cross the placental barrier.  Nivolumab therefore has 
the potential to be transmitted from the mother to the developi[INVESTIGATOR_16103], with greater effects during the  
second and third trimesters of pregnancy.  Nivolumab is not recommended during pregnancy and in women 
of childbearing potential  (WOCBP)  not using effective contraception. (12) 
Animal reproductive studies have not been conducted with Debio  1143. Therefore, it is not known if 
Debio  [ADDRESS_81109]:  
 Agree to use one highly effective method  of contraception as described below. Contraception will 
be required from study entry  up to [ADDRESS_81110] day of study treatment , or 
 Agree to practice complete  sexual  abstinence, when this is in line with the preferred and usual 
lifestyle of the patient ( note: periodic abstinence [e.g., calendar, ovulation, symptothermal post -
ovulation methods] and withdrawal are not acceptable methods of contraception) from study entr y 
up to [ADDRESS_81111] day of study treatment . 
Highly effective methods of birth control  include:  
 Intrauterine device (IUD).  
 Intrauterine hormone -releasing system (IUS).  
 Combined (estrogen and progesterone containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, transdermal) *. 
 | Page 56/107

Protocol    57/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
  Progesterone -only hormonal contraception associated with inhibition of ovulation (oral, injectable, 
implantable) *. 
 Bilateral tubal ligation.  
 Vasectomi zed partner.  
 Double barrier me thods (not highly effective, but acceptable)  
*Note: If hormonal contraception is chosen, the use of a barrier method (preferably male condom) is 
mandatory due to potential risk of CYP 3A4/[ADDRESS_81112] menstruation is within  12 months  before the  
date of the screening visit .  
 
8. STUDY ENDPOINTS, ASS ESSMENTS, AND PROCED URES  
8.1. Endpoints  
8.1.1.  Primary endpoints  
[IP_ADDRESS].  Part A  
The primary endpoint of part A is the RP2D of Debio [ADDRESS_81113] treatment 
and failed a prior PD -1/PD -L1-containing treatment, as p er DLT occurrence in less than one -third of 
evaluable  treated  patients at the RP2D dose level . 
[IP_ADDRESS].  Part B  
The primary endpoint of part B is the confirmed ORR as per RECIST v1.1  and/or GCIG criteria (Cohort 4, 
if applicable) . 
8.1.2.  Secondary endpoints  
Secondary endpoints  for both study parts  (unless otherwise specified)  are:  
 Incidence and severity of TEAEs and clinical laboratory abnormalities, according to NCI -CTCAE 
version 5.0 criteria   
 Changes in vital signs : systolic/diastolic blood pressure, heart rate (both after at least [ADDRESS_81114]), temperature, and weight ; ECG and ECOG -PS 
 Incidence of premature treatment discontinuations and treatment modifications due to AEs and 
laboratory abnormalities  (i.e., treatment compliance)  
 Tumor  response deter mined according to RECIST v1.1 and/or GCIG criteria  (Cohort 4, if 
applicable) :  
o Confirmed ( Part A) and unconfirmed (Parts A and B)  ORR     
o Disease control rate  (DCR) , defined as any response, partial or complete (PR or CR) + 
stable disease (SD)  
o Time -related endpoints as median time  to response, median DOR, median PFS, PFS rate 
at 6, 12 and 1 8 months, median OS , OS rate at 12 months  and 18 months (if data allow)  
 | Page 57/107

Protocol    58/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
  PK parameters of Debio 1143 and Debio 1143 -MET1 as defined in the available population  PK 
model (36) and, if appropriate, post -hoc estimates of areas under the curve ( AUCs ), Cmax, and C min; 
serum concentration v ersus time profiles of nivolumab and, if deemed appropriate, relevant 
nivolumab PK parameters derived from a population PK model. (37) 
8.1.3.  Exploratory endpoints  
Exploratory endpoints are:  
 Potential predictive and PDy biomarkers of Debio 1143 combined with nivolumab , in blood  and 
tumor tissue  
 
 
 Best overall response ( BOR ) evaluation using the novel iRECIST 2017 guideline for 
immunotherapeutics  
 Correlation s between PK disposition of Debio 1143 combined with nivolumab and cl inical response 
and/or any tumor metrics  
 Correlation s between PK disposition of Debio 1143 combined with nivolumab and safety profile , 
and PDy if applicable  
 Correlation s between Debio 1143 and Debio 1143 -MET1 plasma concentrations and changes from 
baseline  QTcF.  
 Correlation s between response, clinical parameters, immune correlates and putative biomarkers, 
 
 Genetic variations in DMET genes associated with differences in the PK disposition of Debio [ADDRESS_81115] scan or MRI imaging of 
the target/non target lesions (38), and/or GCIG criteria using the serum marker CA -125 for Cohort 4, if 
applicable. (39) 
CT scan and MRI will be performed at screening,  then every 8 weeks (± 1-week tolerance window) during 
the first 10 cycles, then every 12 weeks ( ± 1 week) from Cycle [ADDRESS_81116] . For patients who exceptionally  continue study treatment after completion of 13 
cycles , tumor response assessments will continue at 12 -week intervals (± 1 week window) until the end of 
the Main study period , and thereafter at the frequency of local institutional care practice until PD, start of 
any new anticancer therapy, death  or EOT .  
Imag ing will be performed as per site standard but whenever possible using contrast agent at screening and 
during treatment  
CA-[ADDRESS_81117] documentation (+ 1-week 
tolerance window). All patients will have an efficacy assessmen t (CT scan/MRI or serum CA -125 dosage) 
at the time of disease progression and/or treatment discontinuation , whichever occurs first.  
 | Page 58/107

Protocol    59/[ADDRESS_81118]  criteria (novel modified 
RECIST v1.1 gui deline for immunotherapeutics) .(40) These exploratory analys es will be de scribed  in the 
SAP. 
Patients with asymptomatic, but radiologically observed unconfirmed PD as per iRECIST, may continue 
the study treatment, upon both the Investi gator ’s request and the Sponsor ’s agreement, until PD is 
confirmed as per iRECIST or symptoms occurs or Investigator/patient decision to withdraw treatment, 
whichever occurs first.  
[IP_ADDRESS].  Measurability of tumor  lesions  
Patients must have at least one measurable tumor  lesion, according to the RECIST version 1.1 criteria  (38) 
and/or GCIG criteria  (Cohort 4) , if applicable .(39) 
As per RECIST v1.[ADDRESS_81119] one dimension 
(longest diameter in the plane of measurement is to be recorded  except for measurable lymph nodes ) with 
a minimum size of:  
 [ADDRESS_81120] scan (slice thickness ≤5 mm) 
 10 mm caliper measurement by [CONTACT_74321] (lesions which cannot be accurately measured with 
calipers should be recorded as non measurable)  
 [ADDRESS_81121] X -ray 
 Malignant lymph nodes: ≥[ADDRESS_81122] scan (slice thickness ≤5 mm). 
Only the short axis is measured.  
As per G CIG criteria  (Cohort 4 , if applicable ), patients can be evaluated according to CA -[ADDRESS_81123] twice the upper limit of the reference range and within 2 weeks 
before starting the treatment.  
[IP_ADDRESS].  Methods of tumor  assessment  
The choice of the imaging method for tumor  assessment is taken by [CONTACT_779], based on  local feasibility  and 
clinical adequacy . However, the same method of assessment and the same technique must be used 
throughout the trial for a ny given patient. E xtent of disease evaluation  by [CONTACT_74322], abdomen, and pelvis as well as other anatomical 
areas as appropriate  (i.e., CNS imaging fo r symptomatic  SCLC patient s, if appropriate) . Of note, all known 
or suspected disease -involved areas assessed at screening should be at least, included in all subsequent 
assessments. MRI may be used to assess sites of disease not adequately imaged by [CONTACT_74323] e-containing contrast or moderate to severe renal impairment ( calculated 
creatinine clearance <50 ml/min-1). 
For Cohort [ADDRESS_81124] measurable disease in ovarian 
cancer , fallopi[INVESTIGATOR_74272], PPC, and /or endometrial c ancer  with elevated CA -125. 
[IP_ADDRESS].  Tumor  response criteria  
For the evaluation of target lesions by [CONTACT_39694] v1.1 criteria , following definitions  will be applied  (38): 
 CR: Disappeara nce of all target lesions. Any pathological lymph nodes must have reduction in short 
axis to <[ADDRESS_81125] met to qualify as CR.  
 PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline 
sum diameter. PR must be confirmed by [CONTACT_74324] [ADDRESS_81126] met to qualify as PR.  
 | Page 59/107

Protocol    60/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
  Prog ressive Disease (PD) : At least a 20% increase in the sum of diameters of target lesions, taking 
as reference the smallest sum on study (this includes the baseline sum if that is the smallest on 
study). In addition to the relative increase of 20%, the sum m ust also demonstrate an absolute 
increase of at least 5 mm. Note: the appearance of one or more new lesions is also considered 
progression.  
 Stable Disease  (SD) : Neither sufficient shrinkage to qualify for PR, nor sufficient increase to 
qualify for disease progression, taking as reference the smallest sum diameter while on study.  
As per the GCIG criteria  (Cohort 4 , if applicable ), a CA -[ADDRESS_81127] a 50% reduction 
in CA -125 levels from a pretreatment sample  for patients whose CA -125 level was greater than twice the 
upper limit of the reference range when they start ed treatment.   
Progressive disease definitions are provided in Appendix C: Response to treatment criteria .  
8.2.2.  Safety  
Safety assessments will include vital sign measurements, physical examination findings, clinical laboratory 
results, ECOG -PS, ECGs, AE monitoring, and concomitant medications. The s chedule of assessments is 
presented in  Table 8-6.   
[IP_ADDRESS].  Adverse events and concomitant medications  
AEs will be monitored and recorded throughout the study , from the time the informed consent form ( ICF) 
is signed until up to [ADDRESS_81128] nivolumab administration provided no new anti -cancer or end -of-
life care was started earlier. I deally an EOT visit should be planned immediately before whenever is 
feasible . 
AEs will be graded according to NCI -CTCAE version  5.0 (see section 9). 
Concomitant medications and procedures, including blood transfusion s, will be recorded from signing 
informed consent through EOS. Alternative cancer therapi[INVESTIGATOR_74273] -up. 
[IP_ADDRESS].  Physical examination, ECOG score, and vital signs  
A complete physical examination will be performed at screening, on D ays [ADDRESS_81129] three  cycles, 
and then on Day 1 of remaining cycles  and at EOT. The ECOG -PS will always be measured along with 
vital signs comprising systolic/diastolic blood pressure, heart rate (both after at least [ADDRESS_81130]), te mperature, and weight at screening, on D ays 1, 8, 15, and 22  of Cycle 1, and on D ays 1  and 15 of 
other cycle s and at EOT. Height will be recorded only at screening. On dosing days, all assessments should 
be performed predose.  
[IP_ADDRESS].  12-lead ECG  
High -quality, di gital triplicate [ADDRESS_81131] on Day 1 of 
Cycle 1 and  Cycle  3  and on Days 8, 15 and 22 of Cycle 1 at the following 3 time points: pre -, 0.5-2h Debio 
[ADDRESS_81132] -dose (before starting the n ivolumab infusion or after nivolumab perfusion was removed)  and [ADDRESS_81133] be performed prior to PK /PDy  sampling.  There should be at least [ADDRESS_81134] will be consul ted if clinically indicated.  
[IP_ADDRESS].  Safety laboratory  
Safety laboratory measurements are schedu led at screening, C1D1 pre -treatment ( only required if screening 
test were performed > 7 days  prior to C1D1 or if inclusion/exclusion criteria were not met during scre ening ), 
 | Page 60/107

Protocol    61/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
 on D ays 3  (Part A only) , 8, 15, 17  (Part A only) , and 22 of Cycle 1, on D ays 1  and 15 of Cycle 2 and 3, on 
Days 1 of any other subsequent cycle  and at EOT. On dosing days, samples will always be collected predose 
and results reviewed prior to nivolumab infusion, if applicable. All measurements will be performed locally.  
On D ays 3  and 17 of C ycle 1 for patients included in Part A only, serum will be collected and measured for 
total bilirubin (if >ULN: direct  bilirubin  should also be measured ), alkal ine phosphatase (A LP), AST, ALT 
and creatinine.  
For all other visits mentioned above, blood/serum will be measured for the following panels:  
 Hematology:  Hemoglobin, hematocrit, complete blood count (incl. differential) and platelets  
 Chemistry:  Creatinine , sodium, potassium, calcium, total bilirubin (if >ULN: direct bilirubin 
should also be measured ), ALP, AST, ALT, amylase , lipase, lactate dehydrogenase (LDH), total 
protein , albumin and C-reactive protein ( CRP)  
In addition, the following laboratory measurements will be collected :  
 
 on Days 1 and 15  of Cycle 1  and D ays 1 of each subsequent cycle:  
TSH, free triiodothyronine (FT3), free thyroxine (FT4),  
 At screening , the following will also be measured:  HIV, HBV, and HCV serology, CPK and 
troponins , FSH/LH and total testosterone (in male s) or estrogens (in pre-menopausal female  
patients, meaning those whose last menstruation occurred within 12 months of screening date ), 
free-cortisol (at morning) and ACTH.  These dosages could be repeated if clinically  indicated.  
For applicable patients included  in Cohort 4, CA -[ADDRESS_81135] twice the upper limit of the reference range and within 2 weeks before starting the 
treatment . 
[IP_ADDRESS].  Pregnancy test  
For WOCPBP , a serum  test measuring β-HCG wil l be performed at screening. A  predose urine pregnancy 
test at the beginning of each cycle (at C1D1 only required if screening test were performed > 7 days prior 
to C1D1) will be performed as well while on treatment  and up to [ADDRESS_81136] study dose , if 
patients is ongoing follow up . 
8.2.3.  Pharmacokinetics  
PK samples will be collected as described below for determination of Debio 1143  and Debio 1143 -MET1  
plasma concentration , and of nivolumab serum concentrations. In add ition, samples will be collected to 
allow for determination of nivolumab anti -drug antibodies (ADA), if deemed appropriate to support PK 
data interpretation . After completion of the analysis, the remaining PK samples may be stored for up to a 
maximum of 15 years after the end of the study and, if required, may be used for metabolic profiling, for 
further bioanalytical investigations (such as method cross -validation and protein binding), for a 
retrospective examination of safety laboratory tests or proteins i nvolved in the metabolism or the 
pharmacological effects of Debio [ADDRESS_81137]  be recorded. PK samples will be taken in both parts of the 
study  but will differ depending on the administration schedule of n ivolumab (i.e., every 15 days throughout 
the study or every 4 w eeks after C ycle 2) .  
Sampling days and times for PK are listed in: Table 8-1, Table 8-2 and Table 8-3. 
 | Page 61/107

Protocol    62/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020 Lausanne, Switzerland  
  For the determination of Debio 1143 and Debio 1143 -MET1, during Cycle 1 PK samples are to be 
collected  for Part A  on Days 1, 3, 8 15, 17  and 22 and for Part B on Days 1, 8, 15 and 22 . During  
Cycle 3 , PK samples will be collected  for Part A on Days 1, 3, 15 and 17 and for Part B on Days 1 
and 15 . During Cycle 6 on Day 1 (in both parts A and B).  On Days 1, 8, 15, and [ADDRESS_81138] ings on the same day. Samples will be 
analyzed for Debio 1143 and Debio 1143 -MET1 using a validated LC/MS/MS method with a lower 
limit of quantification (LOQ) of 2.5 ng/mL for both compounds.  
 For the determination of nivolumab,  during Cycle 1  PK samples ar e to be collected for Part A on 
Days 1, 3, 8, 15, 17 and 22  and for Part B on Days 1, 8, 15 and 22. During Cycle 3, PK samples 
will be collected for Part A on Days 1, 3, 15 and 17 and for Part B on Days 1 and 15. During Cycle 
6 on Day 1 (in both parts A an d B).  On Days [ADDRESS_81139] two PK 
samplings on the same day. Nivolumab serum concentrations will be determined using a validated 
electrochemiluminescence (ECL) immunoassay with a lower LOQ of 100 ng/mL.    
 For ADA, blood is taken predose on Days [ADDRESS_81140] nivolumab 
ADA will be collected at C13D1  instead of at EOT .  
If deemed appr opriate to support PK data  interpretation , samples will be analyzed for serum ADA entities 
using a validated immunoassay following a tiered testing approach.  
For all PK measurements, the windows of tolerance for sample collection are provided in  Table 8-5. 
 | Page 62/107

Protocol   66/105 
Debio 1143 -106 
 
 Copyright Debiopharm International SA  
Final  version No.  4, 03 April 2020 Lausanne, Switzerland  
 8.2.4.  Pharmacodynamics  and predictive biomarkers  
Tumor biopsies will be collected as follows:  
1. An archived biopsy collected at diagnosis and before any prior PD-1/PD -L1 therapy will be 
provided, if available.  
2. An archived biopsy collected after prior PD -1/L1 therapy will be provided ; if not available  a 
percutaneous or endoscopic biopsy will be mandatorily collected during screening.  
3. A percutaneous  or endoscopic biopsy will be performed (to collect fresh tumor tissue) at the end of 
Cycle 2, if consented and feasi ble (optional) . 
PDy and potentially predictive biomarkers in tumor biopsies may include, but are not limited to  
and markers of cell death and proliferation.  
Blood samples  for PDy measurements will be collected on Days 1 (pre - and [ADDRESS_81141] -dose Deb io 1143), 8, 
15 and 22 (always predose) of Cycle 1, and on Day 1 of Cycle 3 . PDy and potentially predictive biomarkers 
in blood  
 
For all PDy and biomarker measurements, the windows of tolerance for sample collection are provided in  
Table 8-5. 
8.2.5.  Pharmacogenomics and pharmacogenetics  
Blood samples will be collected for mRNA analyses ( pharmacogenomics PGx PAX gene ) at baseline and  
on D ay 15 of Cycle 1 and on Day 1 of C ycle 3. Blood for circulating tumor  DNA ( PGx ctDNA) will be 
collected on Day 1 of Cycle 1, 3 and 6 . A blood sample will be collected at baseline to explore genetic 
variations in DMET genes ( pharmacogenetics PGt) associated with differences in the PK disposition of 
Debio 1143 in combination with nivolumab.  
Back -up samples for PDy, PGx, and PGt will be stored in a sample storage facility pending use for further 
investigations within the scope of the above - mentio ned procedures. The maximum storage period will be  
15 years . 
DNA and RNA samples for future analyses that are not yet defined will be de -identified and re -coded for 
improved protection of patient confidentiality  and stored for 15 years . 
 | Page 66/107

Protocol   68/[ADDRESS_81142] adherence to visit 
intervals. All patients enrolled in the study will attend the study visits as indicated in the study plan . 
Prior to conducting a ny of the screening tests, the I nvestigator or designee will fully explain the study to 
the prospective patient and provide him/her with a copy of the Patient Information Leaflet/ICF.  
If the patient is willing to particip ate in the study, s/he and the I nvestigator or designee will both sign  the 
document.  Of note, CT or MRI scans done before screening, as part of the patient ’s standard of care, if 
within the accepted window up to 8 weeks (±1 week) before C1D1 , can be used instead of repeating a new 
assessment at screening even if it was done before ICF signature, with patient specific agreement, if deemed 
clinically appropriate by [CONTACT_737].  A separate ICF will be signed for participation in the PGx part  of 
the study ( section  8.2.4 ). 
Patients will attend the screening visit(s) within [ADDRESS_81143] treatment cycle. The patient ’s 
suitability for the study will be confirmed by [CONTACT_26141]/exclusion criteria (see section 6). 
 
 | Page 68/107

Protocol  70/105 
Debio 1143 -106 
 
                    Copyright Debiopharm International  SA 
Final version No. 4, 03 April 2020                                                                                                                                            Lausanne, Switzerland  
 *  Examinations should be performed in the following order as applicable: physical examination, vital signs, ECG, safety blood/ur ine samples, followed by [CONTACT_74308]/PDy according to specific 
instructions, and other examinations : Note:  ECGs always have to be taken before PK/PDy sampling.  
 Assessments should be performed on schedule, but occasional changes may be allowed. If the study schedule is shifted, both as sessments and dosing must be shifted to ensure the collection of data is 
completed prior to dosing. Windows :  Laboratory assessments and clinical examinations: Screening period: -4 days (i.e., day -32); EOT visit: ±5 days; follow up visits ±1week, in case of holidays, vacations ; 
other administrative reasons: ± [ADDRESS_81144]/MRI assessment = ± 1 week  
#  Assessments for concomitant medications, pregnancy test and AEs will be performed only at the first  two FU visit s, if applicable. CT scan or MRI assessments will be performed until confirmed iRECIST 
PD, symptomatic PD or any new anticancer treatment or end -of-life hospi[INVESTIGATOR_74251].   
µ  Height only collected at screening . 
[ADDRESS_81145] at the following 3 time points: pre -, 0.5-2h Debio [ADDRESS_81146] -dose (before starting the nivolumab infusion or after nivolumab 
perfusion was removed)  and [ADDRESS_81147] -dose ;There  should be at least [ADDRESS_81148] be performed before 
PK/PDy sampling. ECG reading will be done centrally and also locally for screening purposes.  
2  Pre-dose (as p er section [IP_ADDRESS] ) only required if screening test were performed > 7 days  prior to  C1D1 or if inclusion/exclusion criteria were not met during screening :  
2a  HIV, HCV  and HBV serology testing and CPK and Troponins (I or T whichever is applicable): Only at screening, to be repeated if clinica lly indicated only . 
2b  FSH/LH and total testosterone (in male) or estrogens (in female patients), free -cortisol (at morning) and ACTH: Only at screening and to be repeated if clinically indicated .  
2c  Hemoglobin, hematocrit, platelets and complete blood cell count and differential counts, creatinine, sodium, potassium, calci um, total bilirubin (if >ULN, then  also measure direct bilirubin), ALP, 
AST, ALT, amylase, lipase, LDH, total protein, albumin, CRP.  
2d Part A patients (only): Total bilirubin (if >ULN, then direct bilirubin should also be measured), ALP, AST, ALT, and creatini ne. 
2e  TSH, FT3 and FT4: At  Day 1 and Day 15 in Cycle 1 and every Day 1 of each subsequent cycle.  
2f  CA-125 to be performed at screening  within  4 weeks of C1D1 , exclusively in applicable patients included in Cohort 4, and to be repeated before start of each new cycle if abnormally elevated 
before treatment start, unless PD, any new anticancer treatment or end -of-life hospi[INVESTIGATOR_74252].  
3  In women of childbearing potential only: blood test at screening  (only required if screening test were performed > 7 days  prior to C1 D1), then urine dipstick test alone would be sufficient, at the beginning 
of each treatment cycle while on study up to 5 months after EOT .  
4  Every 8 weeks (±1 week) from first on -treatment scan until Cycle 10, then from Cycle 13, every 12 weeks (± 1 week ) until confirmed iRECIST PD, symptomatic PD or any new anticancer treatment or end -
of-life hospi[INVESTIGATOR_74274]. For patients who continue study treatment in the Extended study period , tumor response assessments will be 
performe d at the frequency of  local institutional care practice until EOT . All patients will have CT or MRI at the time of disease progression, if none previously available. CT or MRI done before scre ening, 
as part of pa tient’s standard of care and  not older than  8 weeks ( +1-week  tolerance ) before C1D1 can be used instead of repeating  a new  assessment at screening even if  done  before ICF signature  [CONTACT_74370] , if deemed  clinically appropriate  by [CONTACT_737] . 
 A contrast enhanced brain CT or MRI is mandatorily at baseline only in SCLC cohort, subsequent brain scans to be done if clin ically indicated.  
5  Up to 3 tumor tissue samples will be collected:  
1) An archived biopsy at diagnosis (before prior PD -1/PD -L1 therapy) = optional;  
2) An archived biopsy if collected after prior PD1/PD -L1 or, if not available a fresh biopsy collected at screening will be mandatory;  
3) A fresh biopsy collected at end of Cyc le 2 (day 28=Day 1 of the following cycle) = optional  
[ADDRESS_81149] nivolumab ADA will be collected at C13D1  instead of at EOT . 
7  Timepoints as specified in  Table 8-4 and windows of tolerance as specified in  Table 8-5.   
7a Only at Cycle 6: PGx ctDNA.  
8  Debio 1143 will be taken orally on D1 -10 and D15 -24 on an empty stomach (patients will fast for [ADDRESS_81150] 1 h after dosing) at app roximately the same time each day. Water is 
permitted freely. A missed dose can be taken as soon as the patient remembers but no later than 6 h after the planned dose. I f >[ADDRESS_81151] elapsed, the missed dose should be skipped and the next dose taken 
accordin g to the regular dosing schedule. A double dose should not be taken to make up for a missed dose. Debio1143 will be   given in the hospi[INVESTIGATOR_307] (before nivolumab infusion whenever is applicable) 
during: Cycle 1 on Days 1,3  (only Part A ), 8, 15, 17  (only Part A) , 22; Cycle 2 on Days 1 and 15; Cycle 3 on Days 1, 3  (only Part A) , 15, and 17  (only Part A) ; and on Days 1 ± [ADDRESS_81152] of the days will be taken at home following relevant medical instructions. A patient’s diary to record tre atment compliance will be provided as a separate document and it will be reconciled with 
the returning capsules by [CONTACT_74309].  
[ADDRESS_81153] 30 minutes on Days 1 and 15, every 4 weeks (i.e., 2 infusions in each 
cycle).  
9a  From Cycle 3 on, the switch to an administration of 480 mg of nivolumab only on Day 1 of each 28 -day cycle is allowed based on the Investigator’s judgment and S ponsor’s agreement.  
± Dispensing of nivolumab will depend on the nivolumab schedule administered from Cycle 3 on wards .   
 | Page 70/107

Protocol  71/105 
Debio 1143 -106 
 
                    Copyright Debiopharm International  SA 
Final version No. 4, 03 April 2020                                                                                                                                            Lausanne, Switzerland  
 10  Continuous AE monitoring, with Investigator’s assessment and documentation at scheduled study visits up to EOT visit and second follow up visit, if applicable. The SAE reporting period is up to [ADDRESS_81154] nivolumab administration . Patients continuing in follow -up (FU) after EOT, in the first and/or second FU visits will have final AEs update of any ongoing toxicity at thi s time , if applicable,  
unless start of new anticancer treatment or end -of-life-care, in which case visit should be scheduled ideally before.  
 11     For Part B, visit s on Cycle 1 and  Cycle  3 on Days 3 and 17 will not be performed  
12    Including information on current and previous tobacco and alcohol use/consumption  
13    Only applicable for patients treated beyond Cycle 13
 | Page 71/107

Protocol   72/[ADDRESS_81155] be recorded in the 
eCRF. Only non -evaluable patients will be replaced , as approp riate. 
[IP_ADDRESS].  End of treatment  
Treatment with Debio 1143 will be continued until any of the following occurs:  
1. Unacceptable toxicity [including, treatment -related NCI -CTCAE v5.0 grade 4 laboratory 
abnormalities (excluding hematological and/or non -febrile asymptomatic neutropenia/leukopenia) ] 
that does not resolve with appropriate standa rd medical measures; or intercurrent illness that would, 
in the opi[INVESTIGATOR_689], affect assessments of clinical status to a significant degree or 
compromise the patient ’s safety;  
2. Permanent discontinuation of  nivolumab;  
3. Treatment delay greater t han 4 and 8  weeks (+1-week tolerance) for Debio 1143 and nivolumab , 
respectively ; 
4. Need to discontinue Debio 1143 due to toxicity despi[INVESTIGATOR_74275] 100 mg/d ; 
5. Prohibited medication as indicated in section  7.7.2  is required/used during the course of the trial. 
In the event a patient is found to be taking a prohibited medication during the trial, the site should 
immediately contact [CONTACT_71908]. The decision to withdraw the patient will be made in 
conjunction with the Sponsor;  
6. If a critical protocol violation occurs that may preclude safety continuation of the study for the 
patient, the Sponsor ’s trial manager will be contact[CONTACT_74325] s if the patient has to be withdrawn 
from treatment;  
7. Symptomatic disease progression documented by [CONTACT_393]  v1.1 or by [CONTACT_74326]  (Cohort 4 , if 
applicable ) in RECIST non -evaluable patients . However, patients may continue study treatment if, 
in the Investigator’s opi[INVESTIGATOR_1649], there is reasonable evidence of ongoing clinical benefit or suggestion 
of “pseudoprogression” without excess risk of toxicity or complications for the  patients .  
8. Confirmed disease progression as per iRECIST ; 
9. Any medical condition that the Investigator or S ponsor determines may jeopardize the patient’s 
safety if he or she continues in the study ; 
10. Withdrawal of patient ’s consent ; 
11. Pregnancy  or breast -feeding a baby ; 
12. Start of any subsequent anti -neoplastic therapy (excluding palliative symptomatic localized RT up 
to 36 Gy total doses for alleviating symptoms e.g. pain, intracranial hypertension, which may 
continue upon the Sponsor ’s agreement, if appropriate) . These patients will continue only in the 
OS follow -up. 
Patients who discontinue treatment for any of the reasons above will have an EOT visit performed 30  days 
(± 5 days) after the last Debio 1143 administration date, but prior to any further therapeutic intervention, 
whenever possible , otherwise an EOT visit should be ide ally scheduled immediately before these events . 
Results of these assessments are to be recorded in the eCRF, together with the reason for treatment 
discontinuation.  
Patients who are taken off study treatment due to AEs are to be treated and followed up ac cording to 
accepted medical practice. All pertinent information concerning the outcome of such treatment is to be 
recorded in the eCRF . 
 | Page 72/107

Protocol   73/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 [IP_ADDRESS].  Follow -up 
Patients with confirmed PD at the EOT visit will have an safety follow -up of  5 months  (±15 d ays) planned 
after the last  nivolumab infusion , provided no new cancer treatment or end -of-life care has been started, 
otherwise this visit may be done immediately before if any of these occur . Patients without PD documented 
at the EOT visit will continue in follow -up for e fficacy every 12 weeks (± 1 -week window) until PD or  start 
of new treatment or end -of-life care , whichever  occurs  first. After PD or new cancer treatment or end -of-
life care starts , patients  will not attend more onsite visits, however, they  and/or relative s may be contact[INVESTIGATOR_530] 
(by [CONTACT_756] , email or m ail) every 4  (± 1) months to update the survival status  until the end of the Main 
study period  ([ADDRESS_81156]) . 
 Follow -up assessments comprise  onsite visits : 
 Safety: For all patients, one first safety follow -up visit will be conducted  90 days ( ±15 days ) after 
last study treatment ; a second safety follow -up visit will be scheduled at 5 months (±15 days) after 
the las t nivolumab infusion, provided the first safety follow -up visit did not overlap (± 1 week), and  
if the patient is  still alive and no further  anticancer  treatment has been started yet..  
 Efficacy: Patients without evidence of PD at EOT will be assessed for PD by [CONTACT_74327] s 
(CT scan or MRI, and clinically)  every 12 weeks (± 1 week )  until symptomatic PD or confirmed 
iRECIST PD or start of any new cancer treatment or end -of-life care or the end of the Main study 
period , whichever occurs first . For pati ents who continue study treatment after the Main study 
period , tumor response assessments will continue at the frequency of local institutional care practice 
until PD, start of any new anti -cancer therapy, death or EO T, whichever occurs first .   
 Survival  calls/contact : [CONTACT_74328]-cancer treatment  will be contact[INVESTIGATOR_530] (by [CONTACT_756], e -mail or mail) every 4 (± 1) 
months  until the end of the Main study period . In case patients cannot be reached, the primary 
physician or the patient ’s partner or family may be contact[CONTACT_74329] . 
 
The following scheme summari zes the temporal relationship between EOT and EOS:  
 
 | Page 73/107

Protocol   74/[ADDRESS_81157] . 
After the End of Main study period  no OS follow -up will be performed for  patients in the Extended study 
period . 
 
8.4. Study duration and EOS  
The study duration for an individual patient completing  13 cycles, will be 52  weeks plus up to 5 months  for 
safety follow -up after EOT, excluding a 4 -week screening period. Patients will atte nd the EOT  as well as 
any follow -up visit s, if applicable .   
Permission to prolong  the study treatment for one additional year can be exceptionally granted by [CONTACT_429], if patients are deriving continuous clinical benefit from the study treatment. Medical justification 
for extending the treatment and the assessment of the risk/benefit balance must be provided by  [CONTACT_74330]. The decision to further extend study treatment will be 
re-evaluated on a yearly basis for each patient.  
 
The total number of onsite visits per patient will depend on the total number of cycles  delivered which is 
based on disease progression, clinical deterioration, investigator criteria, unacceptable toxicity or death 
whichever occurs first.  
The EOS will occur at the End of Main study period or End of Extended study period, whichever occurs 
last.  
The Sponsor will make every effort to supply Debio 1143 and nivolumab to patients who benefit from 
continued treatment; Safety of the patients will be monitored and Health authorities will be notified per 
regulatory requirements . 
Patients will discontinue the study for any of the following reasons:  
1. Patient withdrawal of consent;  
2. Patient lost to follow -up; 
3. Start of end -of-life care;  
4. Death ; 
5. Sponsor or Institutional Review Board (IRB)/ Independent Ethics Committee(s) (IEC) decides to 
terminate earl y the study;  
6. Completion of Main study period , or completion of  Extended study  period , as applicable . 
9. ADVERSE EVENTS   
The I nvestigator is responsible for detection and documentation of events meeting the criteria and definition 
of an AE/SAE as provided in this protocol. At each safety ev aluation during the study, the I nvestigator or 
designee will collect information on unusual manifestations or AEs and SAEs and  will record them on the 
AE page of the eCRF. Their nature, severity, duration, treatment, and rel ationship wi th the IMPs as assessed 
by [CONTACT_941] I nvestigator will be recorded. The Investigator will also indicate whether study treatment was 
discontinued and how the event evolved.  
 | Page 74/107

Protocol   75/[ADDRESS_81158] visit (including disease treated), should be 
considered as an AE. Lack of efficacy is not considered as an AE.  
In particular:  
 Any new sign or symptom reported by [CONTACT_74331].  
 Whenever possible, a diagnosis should be reported on the AE form, instead of signs, symptoms or 
abnormal laboratory values.  
 Pregnancy is not to be considered as an AE; how ever, it must be monitored as described in Section 
9.5. 
 Each new epi[INVESTIGATOR_44715] a chronic disease (e.g., hay fever, allergy, etc.) from the screening visit should 
be reported as a new AE.  
AEs are illnesses, signs or symptoms (including abnormal laboratory find ings) occurring or worsening in 
the course of the study. AEs can be serious or non -serious. They may or may not lead to the withdrawal of 
the patient from the study.  
9.1.2.  Serious adverse event  
A SAE is defined as any untoward medical occurrence that at any dose:  
 Results in death;  
 Is life threatening (i.e., puts the patient at immediate risk of death);  
 Requires inpatient hospi[INVESTIGATOR_15574];  
 Results in persi stent or significant disability/incapacity;  
 Is a congenital anomaly/birth defect, or  
 Is otherwise medically significant: Important medical events that may not immediately be life 
threatening or result in death or hospi[INVESTIGATOR_11956], but that jeopardize the pa tient or require 
intervention to prevent one of the outcomes listed in the definitions above shall also be considered 
as serious.  
All AEs that do not correspond to the definition of SAE are considered as non -serious.  
9.1.3.  Unexpected or expected adverse events  
An unexpected AE is an event whose nature or severity is not consistent with information on the condition 
under study and/or not consistent with the applicable product information, i.e. the Investigator Brochure.  
All AEs that are suspected to be related to the IMP(s) and that are both unexpected and serious are 
considered to be Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs).  
9.1.4.  Severity of adverse events  
AEs will be graded by [CONTACT_941] I nvestigator or designee according to NCI -CTCAE, version 5.0.  
 | Page 75/107

Protocol   76/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 If a particular AE ’s severity is not specifically graded by [CONTACT_74332], the Investigator is to 
revert to the general definitions of grades [ADDRESS_81159] medical judgment:  
 Grade 1 (mild): Causing no limitation of usual activi ties, the patient may experience slight 
discomfort.  
 Grade 2 (moderate): Causing some limitation of usual activities, the patient may experience 
annoying discomfort.  
 Grade 3 (severe): Causing inability to carry out usual activities, the patient may experien ce 
intolerable discomfort or pain.  
 Grade 4:  Life-threatening  
 Grade 5:  fatal 
 
9.1.5.  Relatedness to IMPs  
The I nvestigator or designee will determine the relationship between the AE and the IMPs according to the 
following criteria:  
Reasonable causal relationship:  
A clinical event, including laboratory test abnormality,  
 Where time relationship to drug administration is at least reasonable, and  
 Where other causes (e.g. underlying disease) may not by [CONTACT_74333], and/or  
 Where a clinically reasonable response occurs on withdrawal (dechallenge).  
No reasonable causal relationship:  
A clinical event, including laboratory test abnormality,  
 Where time sequence to drug administration is not reasonable, or  
 Where other causes (e.g. underlying disease) can by [CONTACT_74334].  
9.1.6.  Adverse events of special interest  
AESIs are  
1. for Debio 1143:  
a. AST or ALT increases >[ADDRESS_81160] associated with total bilirubin >[ADDRESS_81161] and ALP <[ADDRESS_81162]  
b. Lipase or amylase increases > [ADDRESS_81163] two consecutive 
readings or other ECG abnormalities such as Torsade de Pointe, ventricular tachycardia, 
ventricular fibrillation, flutter or any other new cardiac abnormality at the ECG or during 
the physical examination co nsidered as clinically significant.  
2. for nivolumab:  
a. Any AEs that are suspected to be immune -related or infusion -related including drug 
hypersensitivity, immune -related pneumonitis, immune -related colitis, immune -related 
hepatitis, immune -related endocrinopathies such as: thyroid disorders, adrenal 
insufficiency, new onset type I diabetes mellitus, pi[INVESTIGATOR_74276]; or immune -related 
 | Page 76/107

Protocol   77/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 nephritis and renal dysfunction and other immune -related AEs such as: myositis, 
myocarditis, Guillain -Barré syndr ome or uveitis of any grade  
All AESIs, occurring after treatment start  on C1D1  must  be reported  to the sponsor  in the appropriate eCRF 
pages . When reporting these cases, it has to be specified in the eCRF whether the case is serious or non -
serious. If the  AESI(s) is/are serious or considered to be a DLT, then it has to be properly reported within 
24 hours of acknowledgement and all applicable SAEs reporting guidelines should be followed (as 
described in section 9.2) including the reason why it is considered serious.  
 
9.2. Reporting of serious adverse event s to the S ponsor  
9.2.1.  Reporting during the study  
The Investigator must notify the Sponsor/Clinical Research Organization (CRO) of all SAEs within 24 
hours of awareness  by [CONTACT_74335]. Once the AE is selected as a Serious 
event and the form is saved in the eCRF an email not ification will be sent automatically to the Sponsor ’s 
Pharmacovigilance department.  
If for any reasons the eCRF is not available, as  a back -up option  the SAE can be declared by  e-mail using 
the Debiopharm International (DPI) paper 'SAE Report form', or by [CONTACT_756].  
1. When reported by e -mail, the 'SAE Report form' will be sent to the following e -mail address: 
‘ ’ ( ) or CRO email 
addre ss if applicable.  
2. When reported by [CONTACT_756], the DPI [INVESTIGATOR_74277].  
This should be followed by [CONTACT_74336].  
Notification of SAEs does not depend on their relationship with the IMP(s). All SAEs regardless of their 
relationship with the study drugs and occurring until the last study  visit will be reported as described above .  
9.2.2.  Reporting post -study  
Any SAE occurring up to [ADDRESS_81164] be followed up:  
 To resolution (the patient's health has returned t o the baseline status or all variables have returned 
to normal), or  
 Until stabili zation of the event has occurred (the I nvestigator does not expect any further 
improvement or worsening of the event), or  
 Until the event is otherwise explained regardless o f whether the patient is still participating in the 
study.  
Some events, such as metastases, are often ongoing; however, once these events have be en determined by 
[CONTACT_2026] I nvestigator to be stable or chronic, he/she may consider the event to be resol ved or resolved 
with sequelae.  
 | Page 77/107

Protocol   78/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 The Investigator will notify the Sponsor of any follow -up information  in the eCRF pages  within 24 hours 
of new information awareness (see section 9.2.1 ). 
9.4. Procedure for SAE communication  
If required by [CONTACT_74337] e local regulations, the I nvestigator will promptly notify the relevant IRB/ IEC (in 
addition to the S ponsor) of any SAE (including po st-study SAEs and follow -up information) that occurred 
at their site or was brought to their attention by [CONTACT_1034]. The Investigator will verify that the IRB/ IEC 
acknowledges receipt of the notification.  
In case of Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) , unusual increase in the frequency 
or the severity of expected SAEs  or new safety data which could have an impact on the overall expectedness 
of a SAR or change in the safety profile of the investigational product(s) that requires the in formed consent 
to be updated, the Sponsor will prepare investigator safety reports according to regulatory requirements 
relating to safety reporting.  
This report will be communicated by [CONTACT_74338] -[ADDRESS_81165] be 
followed -up until pregnancy outcome is known.  
Pregnancies shall be r eported from t he Investigational site to the S ponsor using a Pregnancy Report Form. 
The same process and timelines as defined for SAE reporting apply ( section  9.2.1 ). In case of serious 
outcomes experienced by [CONTACT_74339]/or the fetus/child (definition of ‘seriousness ’ in section 9.1.2 ), the  
events should be reported as SAEs using the SAE report form. This procedure applies to pregnancies in 
female patients as well as to those in female partners of male patients.  
10. MONITORING AND STUDY  COMMITTEES  
10.1.  Monitoring  
The study S ponsor is Debiopharm Inter natio nal S.A  (DPI) , Lausanne, Switzerland . 
A designated Contract Research Organization (CRO) will perform site monitoring.   
At mutually convenie nt times during the study, the I nvestigator will let DPI [INVESTIGATOR_74278], i.e., patient office, hospi[INVESTIGATOR_307], clinic, and laboratory records.  
At timely intervals, and at the closing of the study, all IMPs will be accounted for and disp ensing records 
made available to DPI [INVESTIGATOR_74279] (see also sections 7.3 and 7.6). 
In case eCRFs require support information, DPI [INVESTIGATOR_74280]. All the necessary steps will then be taken to protect patient identity. Adherence to local and 
national laws governing protection of patient identity will be ensured.  
10.2.  Study committees  
10.2.1.  Data Safety Monitoring Committee  
A Data Safety Monitoring Committee (DSMC)  will overview study conduct during  both parts A and B. It 
will be  composed of at least all actively involved investigators (or their designee ), the Sponsor Medical 
Director  and the CRO medical monitor  as voting members and  will meet regularly to overview the clinical 
safety of the patients , laboratory data and the conduct of the study . Ad hoc members may be invited as 
needed.  
 | Page 78/107

Protocol   79/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 During P art A , calls will be scheduled monthly  or according to patient recruitment as necessary . A charter 
will be provided as a separate document.  
During part B the DSMC will meet approximately every three  months, but more frequently if needed due 
to rapid recruitment . A charter will be provided separately.  
11. DATA MANAGEMENT AND STATISTICAL ANALYSIS  
11.1.  Sample size  
 Part A   
The sample size will be determined by [CONTACT_74340] e observed 
toxicities. Given that (i) a maximum number of two dose levels will be explored, (ii) a classical 3+3 design 
will be used and (iii) at least 6 patients need to be treated at the RP2D before the phase II part starts formally, 
between 3 -12 evaluab le patients will be included.  Patients non -evaluable for DLT will be replaced as 
appropriate . 
 Part B  
The efficacy of Debio [ADDRESS_81166] v.1.1 and/or GCIG (Cohort 4, if applicable). Assuming a futility 
response rate of 5% below which the response is considered not clinically meaningful and a true response 
rate of 15% which is considered clinically meaningful, with a maximum sample size of [ADDRESS_81167] 80% probability that the true response rate is 
>= 15%, which corresponds to 4 responses or more. A cohort will be declared futile if there is suffi ciently 
low probability (20%) that the tru e response rate exceeds 5%. The first futility assessment will be performed 
after the first 8 patients are assessed and the second one after 11 patients. Futility assessment will be 
performed using the unconfirmed responses.  
The total sample size will be b etween 32 (if all cohorts are futile) and 60 evaluable patients (if none of the 
4 cohorts is futile) and no patient replacement occurs.  
11.2.  Data management and handling  
11.2.1.  Data capture, verification and validation  
Data entry, verification and validation will be  captured using an electronic data capture (EDC) system. EDC 
system is a web -based computerized system designed for the collection of clinical data in electronic format 
(electronic case report forms (eCRF)); accessed via an Internet URL link.  
EDC system a ccess (username [CONTACT_2383]) will be provided upon completion and confirmation of 
prerequisite training. Username [CONTACT_74371].  
The Investigator and/or designee will accurately, completely, and in a ti mely manner enter the required 
study data into the eCRFs. One eCRF will be completed for each patient.  
Validation of the eCRF data is performed by i) automatic EDC system checks and ii) other data review 
tools, such as data listings. Data validation may re sult in the generation of queries. A query is a request for 
further information or clarification which may lead to data change. All queries (automatic and manual) will 
be generated and tracked within the EDC system until resolution. Manual queries can be r aised directly into 
the EDC system by [CONTACT_74341].  
CRA review, source data verification, is conducted on an ongoing basis and is confirmed in the EDC system. 
In general , the CRA review is focused on the quality and integrity of the eCRF data.  
 | Page 79/107

Protocol   80/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 Data management review is conducted on an ongoing basis, includes the review of all automatic system 
generated queries and is confirmed in the EDC system. In general, data management re view is focused on 
the completeness and coherency of the eCRF data, and also includes reconciliation of external data versus 
eCRF data.  
Medical review is conducted on an ongoing basis. In general, this review is focused on the completeness 
and coherency of  the safety data.  
The EDC system audit trial captures all eCRF data related activities such as: data entry, data modifications, 
data verification, data lock, e -signature [CONTACT_30038].    
eCRF data will be extracted from the EDC system into SAS® on a periodic basis and at defined study 
timepoints for  statistical analysis.  
11.2.2.  Missing data handling for statistical analysis  
For missing or partial AEs and concomitant medications dates, conservative conventions will be applied in 
order to assign the even ts to corresponding periods. AE will be considered as treatment emergent and the 
medications will be considered as concomitant if the missing/partial dates can not definitively exclude the 
treatment period . 
Dates of remote events (e.g., medical history) may  be partially incomplete, as the day and/or month may 
be unknown. Any missing day will be replaced by [CONTACT_941] 15th and any missing month by [CONTACT_11713].  
Imputation of missing data will be described in detail in the statistical analysis plan.  
11.3.  Handling of values below  (or above) a threshold  
To derive PK parameters and for summary statistics (except for calculations involving logarithmic 
transformations), plasma levels reported as below the LOQ will be considered as [ADDRESS_81168] quantifiable concen tration. When a plasma level is below LOQ between two quantifiable 
concentrations  within a dosing interval , it will be set to ½ LOQ.  
For summary statistics where calculation involves logarithmic transformations (including geometric mean 
calculation), plas ma levels below LOQ will be set to ½ LOQ.  
For pharmacodynamics parameters and safety laboratory tests, values below or above the limit of detection 
will be substituted with the lower/upper limit of detection.  
11.4.  Handling of unscheduled assessments or retests  
The u nscheduled assessments and the retests performed before the treatment start will be included in the 
definition of the baseline which is the last value before the treatment start between the planned assessments, 
unscheduled assessments and retests.  
After treatment start , the unscheduled assessments and retests will be used only in the derivation of 
endpoints that are not related to a specific timepoint (e.g. worst laboratory parameter level on -treatment). 
In the timepoint analyses, the original/planned values will be used.  
11.4.1.  Derived parameters and endpoints  
[IP_ADDRESS].  Efficacy  
Patients without any new anticancer therapy or PD will be assessed for anti -tumor efficacy every 8 weeks 
(±1 week) during the first 10 cycles and then every 12 weeks (± 1 week) from Cycle [ADDRESS_81169]. For patients who continue study treatment after the Main study period, tumor 
 | Page 80/107

Protocol   81/[ADDRESS_81170] version 1.1 (38) or GCIG criteria (39) (Cohort [ADDRESS_81171] non -evaluable 
patients)  will be assessed in the efficacy and ITT population s. CR and  PR must be demonstrated by 
[CONTACT_74342] (CT scan/MRI or CA -125 dosage ) and confirmed [ADDRESS_81172] scan /MRI or CA -[ADDRESS_81173]. (40) These exploratory 
analyses using iRECIST guideline will be presented in detail in the SAP.  
In case of premature discontinuation with SD at the EOS visit, this SD will be included in the derivation of 
efficacy parameters  only if the assessment has been performed at least [ADDRESS_81174] until study data cut -off. 
The confirmed response will be used in the primary ORR a nalysis  while a s econdary analysis will be 
performed using the unconfirmed response.  
 Objective response is derived as any PR or CR recorded after the start of study treatment until 
disease progression/recurrence is documented, a new systemic anti-cancer therapy is started or 
analysis cut -off, whichever occurs first.  
 BOR  is the best response (CR, PR, stable disease or disease progression) recorded after the start of 
study treatment until disease progression/recurrence is documented, a new systemic anti-cance r 
therapy is started or analysis cut -off, whichever occurs first.  
 Disease control  is derived as any CR, PR or stable disease reported during the study   
 Duration of response  is the time from documentation of tumor  response to disease progression , 
start of a systemic new anti -cancer therapy or analysis cut -off, whichever occurs first . 
 PFS duration  is defined as the time elapsed between treatment initiation and tumor  progression or 
death from any cause, whichever occurs first. Censoring to the last assessment  will be applied in the 
following situations: a) lost to follow -up, b) no progression before analysis cut-off, c) start of a new 
systemic anti -cancer therapy. The median P FS and the PFS rate at 6 , 12 and 18  months will be 
derived from the Kaplan -Meier curv es.  
 OS is defined as the time elapsed between treatment initiation and death from any cause. In the main 
analysis , censoring to the last assessment will be applied in the following situations: a) lost to follow -
up, b) alive at analysis cut-off. A sensitiv ity analysis will be performed by [CONTACT_74343] a new systemic anti-cancer therapy. The median OS and the OS rate at 12 months  
will be derived from the Kaplan -Meier curves.  
[IP_ADDRESS].  Safety  
A TEAE is any new, related or non -related, undes irable medical occurrence or change of an existing 
condition in a patient that occurs during the treatment -emergent period, starting or worsening on or after 
the first study drug administration and up to 5 months (±15 days) after last nivolumab infusion, o r the 
earliest date of new anticancer therapy – [ADDRESS_81175].  
[IP_ADDRESS].  Pharmacokinetics   
Based on sparse plasma concentration s, Debio 1143 and Debio 1143 -MET1  PK parameters will be 
evaluated from the population PK disposition model available to date (36) via a population approach with 
nonlinear mixed effects modelling using NONMEM® (ICON Solutions).  If appropriate, post -hoc estimates 
 | Page 81/107

Protocol   82/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 of AUCs, C max and C min will be derived for Debio 1143 and Debio 1143 -MET1. Inter - and intra -individual 
PK variability will be assessed by [CONTACT_74344] t rials.  
For nivolumab, serum  concentration versus time profiles will be analy zed. If deemed appropriate, 
nivolumab concentrations will be integrated in a population PK model (37) to estimate relevant PK 
parameters.   
These population PK analys es will be described in a separate analysis plan  and reported separately . 
If data allow, a non -compartmental PK  analysis for Debio 1143 and Debio 1143 -MET1 may also be 
performed using Phoenix ™ WinNonlin® (Certara L.A.) . As appropriate, this analysis will also be described 
in a separate analysis plan.  
[IP_ADDRESS].  Coding  
Medical history, AEs, concomitant treatments and/or procedures, and surgeries will be coded per SOC and 
PT using the last available version of the Medical Dictionary for Regulatory Activities (MedDRA). Past 
and concomitant medications will be coded per anatomical therapeutic chemical (ATC) class levels [ADDRESS_81176] available World Health Organi zation (WHO) Drug Dictionary.  
11.5.  Selection of patients for statistical analysis  
11.5.1.  RP2D  population (part A  only) 
Patients will be considered as not evaluable for DLTs and excluded from the RP2D population, if they did 
not receive at least 70% of Debio 1143 (i.e., a maximum of 6 missed Debio 1143 doses) and at least one  
nivolumab dose  as planned  in Cycle 1 for any reason other than DLT . 
Patients not evaluable for DLT will be replaced if there are  less th an 3 evalu able patients by  [CONTACT_9084] . 
If a treatment modification during the DLT period leads to a potentially non -evaluable patient, the final 
decision regarding the patient ’s evaluability will be taken only at the end of his/her DLT period. If the 
patient experiences a DLT, he/she will be considered as evaluable regardless his/her exposure.   
11.5.2.  Safety population  
The safety population is defined as enrolled patients who received  at least one  dose of any study drug.  
11.5.3.  ITT population  
The intention -to-treat (ITT) population  will include all enrolled patients  who took at least one dose of any 
study drug . This is to exclude the patients who took no trial medication. Therefore , the ITT population is 
identical with the current Safety population.  
11.5.4.  Efficacy population  
The efficacy  population is defined as p atients who have : 
 measurable disease according to RECIST  v1.1 and/or GCIG  criteria  (Cohort 4, if applicable)  
and 
 a baseline tumor assessment and at least one post-baseline  tumor assessment , either CT or MRI for 
RECIST evaluable p atients, or CA -125 dosage performed after baseline, if applicable,  
or  
 treatment discontinuation occurred before the efficacy assessment was done due to treatment 
failure, defined as: death, unacceptable toxicity, clinical deterioration and/or symptoms wo rsening  
 | Page 82/107

Protocol   83/[ADDRESS_81177] the patient 
benefit/risk  balance  (i.e., non-eligibility  criteria ), efficacy data assessed after such protocol violations will 
be excluded from the efficacy analysis,  as appropriate,  but the patient will be kept in the efficacy population. 
This will be described in detail in the statistical analy sis plan ( SAP).  
11.6.  Statistical analysis  
The statistical analysis described below corresponds to what is foreseen during the planning of this study. 
If during the study , circumstances should arise that render this analysis inappropriate, or if in the meantime 
improved methods of analysis should come to light, a different analysis may be performed . Therefore, the 
definit ive statistical analysis will be described in the SAP. Any deviations from this plan, reasons for such 
deviations, and all alternative or additional statistical analyses that may be made , will be described in the 
final report.  
Ordinal and continuous data will be presented, in the form of descriptive statisti cs, as number of patients, 
mean, standard deviation, minimum, median, maximum, and 95% confidence interval (CI). In addition, for 
PK parameters (see section [IP_ADDRESS] ), the geometric mean, 90% CIs of geometric means, the standard 
deviation of the geometric means, and geometric coefficient of variation (CV% ) will be presented if 
applicable. Categorical data will be presented, using contingency tables w ith absolute and relative 
frequencies.  
For Part A, the results will be reported overall and by [CONTACT_2715], while for Par t B, the results will be reported by 
[CONTACT_13153] (except for efficacy in case of heterogeneous data and futile cohorts).  
All data analy ses will be performed using the statistical softwares SAS®, R, NONMEM®, and Phoenix ™ 
WinNonlin®. 
11.6.1.  Part A  
Due to the nature and design of the study, the statistical analysis of the dose -optimization part will be mostly 
descriptive unless otherwise specified.   
11.6.2.  Part B  
Part B of the study is an exploratory basket trial intended to assess the preliminary efficacy of Debio 1143 
in combination with nivolumab in four indications  and p romising efficacy results should be further 
evaluated in subsequent trials. Due to the exploratory nature of the trial , there will be no formal hypotheses 
testing.  
Bayesian posterior probability will be used for the early stoppi[INVESTIGATOR_74281]. 
The claim of efficacy will be based on the primary endpoint ( confirmed ORR), while the futility stoppi[INVESTIGATOR_74282] .  
Recruitment will be stopped in the futile cohorts. A homogeneity test will be conducted in the non -futile 
cohorts  showing a confirmed response rate of at least 15% . In case of  homogeneous response rates across 
the cohorts, efficacy data will be pooled and all the efficacy endpoints will be reported overall and by 
[CONTACT_9084] . Otherwise , the efficacy will be reported by [CONTACT_74345]. The efficacy of the futile cohorts and of the 
cohorts with less than 15% response rate will be reported separately.   
All other endpoints such as demographics, baseline characteristics, safety, PK, PDy, etc. will be presented 
overall and for each cohort.  
 
 | Page 83/107

Protocol   84/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 11.6.3.  Interim analyses  
Part A  
No formal interim analysis will be performed during the dose -optimi zation  part; review of ongoing data 
will be done when dose  increase, repeat or decrease  is to be decided  at DSMC meetings .  
Part B  
There will be two interim futility analyses in each cohort. The cut-off for the futility analyses is defined as 
the time when the last ongoing patient from the first 8/[ADDRESS_81178] v1.1  and/or GCIG criteria  (if applicable)  will be 
checked vs. the futility boundaries in each cohort independently.  
Bayesian posterior probability of th e unconfirmed objective rate will be used for the early stoppi[INVESTIGATOR_74283] .  
 A general  confirmed response rate of 15% is considered as promising, justifying further development. This 
corresponds to approximatively 17% unconfirmed response rate.  On the other hand, 5% is considered to be 
the general futility response rate  (unconfirmed) . 
Assuming a probability confidence threshold for futility stoppi[INVESTIGATOR_31081] 20%, and a maximum sample size of 
15 patients by [CONTACT_9084], the futility stoppi[INVESTIGATOR_74284]:   
 [ADDRESS_81179] interim analysis and  
 ≤[ADDRESS_81180] v1.1 and/or GCIG 
criteria  (if applicable)  after the 8th evaluable patient is assessed, futility will then be concluded and the 
recruitment will be stopped in the corresponding cohort. In case at least one unconfirmed re sponse is 
documented in the first [ADDRESS_81181] 
11 evaluable patients, the re cruitment will continue up to 15 evaluable patients; otherwise the recruitment 
will be stopped. The early stoppi[INVESTIGATOR_74285].  
11.6.4.  Final analysis  
The final analysis will be performed within one year of the End of the Main study period ( which lasts until  
[ADDRESS_81182] ). 
Data collected after the Main study period for patients entering the Extended study period, will be 
summarized using descriptive statistics and included in an addendum to the Final  CSR . 
The main study results will be presented separately for both study parts . An exploratory analysis will be 
conducted by [CONTACT_74346], baseline characteristics and safety, data from both study parts. In 
addition, if homogeneity tests a llow, and any specific cohort population is adequately represented in Part 
A, efficacy data form both study parts may be pooled expl oratory, as appropriate.  
In Part B, according to the Bayesian posterior probability used in each non -futile cohort at the final efficacy 
assessment conducted in the [ADDRESS_81183] four 
confirmed responses are reported in the se 15 evaluable patients.  This efficacy boundary was derived 
assuming a confirmed ORR of 1 5% and a probability confidence threshold of efficacy of 80% . 
A homogeneity test of the primary endpoint will be conducted in the non -futile cohorts  showing a confirmed 
response rate of at least 15% . In case of homogeneous response rates across the cohorts , efficacy data will 
be pooled and all the efficacy endpoints will be reported overall and by [CONTACT_9084] . Otherwise , the efficacy will 
 | Page 84/107

Protocol   85/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 be reported by [CONTACT_74345]. The efficacy of the futile cohorts  and of the cohorts with less than 15% response 
rate will be re ported separately.   
All other endpoints such as demographics, baseline characteristics, safety, PK, PDy, etc. will be presented 
overall and for each cohort.  
[IP_ADDRESS].  Disposition of patients, demographic and baseline data  
Disposition of patients enrolled and treated will be presented with reasons for patient discontinuation if 
applicable. The number of patients at each study visit will be tabulated. Frequency distribution of adherence 
to the visit schedule and assessments will be given according to the pro tocol schedule.  
Demographic and baseline data will be summari zed overall and by [CONTACT_74347]. Ordinal 
and continuous data will be presented as descriptive statistics, i.e. median, mean, standard deviation, min -
max and 95% CI. Characterist ics of baseline categorical parameters will be presented as contingency tables 
with absolute frequencies and percentages, and with 95% CI where applicable.  
Medical history and p rior anti -cancer treatments will be presented for the safety population as the 
number/ proportion of patients and the number of mentions. Medical history and p rior anti -cancer treatments 
will be classified by [CONTACT_74348], per SOC and PT and/or by [CONTACT_74349]  2 and 4.   
[IP_ADDRESS].  Investigational medicina l product, concomitant medication, 
and illnesses  
Extent of exposure  
Extent of exposure will be summari zed in the safety, efficacy and RP2D populations for Debio 1143 as 
follows:  
• The number of administrations and total cumulative dose will be summari zed as descriptive 
statistics;  
• Treatment delays and dose reductions will be summari zed as descriptive statistics;  
For nivolumab , the extent of exposure will be summari zed in the safety, efficacy and RP2D populations as 
follows:  
• The number of cycles and total c umulative dose will be summari zed as descriptive statistics;  
• Treatment delays and dose reductions will be summari zed as descriptive statistics;  
• The treatment -specific window used for the selection of the “exposure on -treatment period ” safety 
and efficacy a ssessments is defined as:  
• Debio 1143: last administration + 5 half lives (~32 hours)  
• Nivolumab: last administration + 14 or 28 days as applicable (depending on nivolumab schedule 
used in last cycle)  
Concurrent diseases, concomitant medications, procedures and surgeries will be presented in the Safety 
population as the number/ proportion of patients and the number of mentions. Concomitant procedures and 
surgeries will be classified by [CONTACT_74348], per SOC and PT. Concomitant medications will be 
presented using the WHO drug dictionary by [CONTACT_74350]  2 and 4.  
Concomitant medications will be split into three categori es: pre -medications (medications administered 
only before treatment start), co -medications (medications administered during investigational product 
administration) and post -medications ( new anticancer therapi[INVESTIGATOR_74286]). If applicable,  
procedures and surgeries will be split as pre -, concomitant, and post -treatment.  
 | Page 85/107

Protocol   88/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 ECOG -PS 
ECOG -PS will be presented as contingency table s by [CONTACT_74351].  
ECG  
Digital High -Quality ECG will be obtained by [CONTACT_74352] -treatment, on -treatment, and change from 
pre-treatment to on -treatment will be  analyzed centrally and will be  presented as descriptive statistics , as 
approp riate. The number and percentage of patients with significant QTcF prolongation will be reported as 
contingency tables. Significant QTc F prolongation is defined as an interval >500 ms or an interval which 
increases by 60 ms over baseline. Several QTc prolongation analyses using different categories limits 
(>450, >480  and >500 ms, as well as increases from baseline of >30  ms and >60  ms) will be performed as 
per ICH -E14 guidelines.  
[IP_ADDRESS].  Pharmacokinetics   
PK concentrations will be presented by [CONTACT_74353] (Part A) and overall and by [CONTACT_9084] (Part B) 
as descriptive st atistics for Debio [ADDRESS_81184] deviation, minimum, 
median, maximum, CV%, geometric mean, standard deviation of the geometric mean, geometric CV%, 
and 90% CI of geometric mean.  
Graphic displays of plasma concentration vs . time curves will be presented individually by [CONTACT_74354] ± arithmetic standard deviations using linear/linear scales and as geometric means ± 
geometric standard deviati ons using log10/linear scales.  
PK parameters will be listed by [CONTACT_74355].  
PK data will be presented similarly for nivolumab, when applicable.  
The relationship between PK disposition and clinical response, PDy,  QTcF v ariations,  safety and g enetic 
variations in DMET genes will be analy zed by [CONTACT_74303].  
[IP_ADDRESS].  Pharmacodynamics  
 
Pharmacodynamics at baseline, at any scheduled visit, and the corresponding fold changes (log2) from 
baseline will be p resented using descriptive statistics. The maximum increase on -treatment will be similarly 
presented, along with its fold change from baseline.  
Graphics displaying PDy parameters absolute value s and fold changes from baseline will be presented as 
individua l curve s and mean curve s (±standard deviation)  vs. time.  
Exploratory data analyse s will be conducted to investigate the relationship between PDy biomarkers and 
efficacy and safety parameters by [CONTACT_74306] . 
[IP_ADDRESS].  Pharmacogenetic  factors and predictive biomarkers  
Pharmacogenetic factors and predic tive biomarkers assessments are exploratory. The relationship between 
efficacy , pharmacogenetic factors and predic tive biomarkers will be analy zed by [CONTACT_74307].  
12. SPONSOR AND INVESTIG ATOR OBLIG ATIONS  
12.1.  Good Clinical Practice and Declaration of Helsinki  
This trial will be conducted in compliance with the International Conference on Harmoni zation (ICH) Good 
Clinical Practice (GCP) guidelines (and the ethical principles that have their origin in the Declaration of 
 | Page 88/107

Protocol   89/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 Helsinki see Appendix  A in Section  14.1 and its subsequent amendments) as well as with  all the applicable 
local regulations for cl inical trials involving human subjects.  
12.2.  Institutional Review Board / Independent Ethics Committee  
The study protocol, ICF, and any other relevant study documentation must be reviewed and approved by 
[CONTACT_4215]/ IEC that conforms to local laws, prior  to enrolment of patients into the study. I t is the 
responsibility of the I nvestigator to assure that all aspects of the institutional review are conducted in 
accordance with local regulations and applicable ICH GCP. A letter documenting IRB/ IEC approval (in 
which the protocol [title and protocol number  is specifically identified) and a list of IRB/ IEC members and 
affiliations mus t be received by [CONTACT_941] S ponsor prior to initiation of the study. If applicable, t he Investigator is 
responsible for sub mitting an Investigator Progress Report to the IRB/ IEC in time for the IRB/ IEC to carry 
out review prior to the expi[INVESTIGATOR_74287]/ IEC approval. This is required as long as the study 
is ongoing.  
The I nvestigator will inform the IRB/ IEC of the completion or early termination of the study.  
Every serious or unexpected AE that might affect patient safety must be brought to the attention of the 
IRB/ IEC by [CONTACT_941] I nvestigator. Similarly, every report from the Sponsor concerning an AE must be brought  
to the attention of the IRB/ IEC by [CONTACT_941] I nvestigator if applicable as per local guidelines.  
12.3.  Informed consent  
The I nvestigator or designee will ensure that signed ICF in accordance with the Declaration of Helsinki, 
local laws, and all applicable regulatory requirements, is obtained from each potential patient prior to any 
study related procedure. The informed consent process will be documented.  
Each patient will be given oral and written information in an easily understandable language  describing the 
nature  and duration of the study. This must take place under conditions where the patient has adequate time 
to consider the risks associated with study participation.  
A least one original of the ICF will be signed by [CONTACT_102] (and/or legal authorized represe ntative 
[guardian, next of kin, or other authorized indi vidual] if applicable) and the I nvestigator or designee. One 
signed original or a copy of the original will be given to the patient and the original one will be kept in the 
Investigator file at the st udy site.  
12.4.  Patient confidentiality  
The I nvestigator will ensure that patient reports and samples are identified only by a patient identifier to 
maintain patient confidentiality. All patient study records will be kept safely in an access -controlled area. 
Identification code lists linking the patient names to identifiers sh all be stored separately from patient 
records. Clinical information will not be released without written permission from the patient, except for 
monitoring  and/or audit  by [CONTACT_74356] S ponsor.  
12.5.  Data reporting and electronic case report forms  
The Investigator and/or designee will accurately, completely, and in a timely manner enter data resulting 
from execution of the protocol into eCRFs  made available by [CONTACT_941] S ponsor via an EDC  system, i.e. a web -
based computerized system designed for the collection of clinical data in electronic format. One eCRF will 
be completed for each patient and must be electronically sig ned and dated by [CONTACT_2026] I nvestigator or 
may b e signed by [CONTACT_74357] -investigator on behalf of the principal I nvestigator. Corrections in eCRFs 
will be recorded in an audit trail. The data will be extracted from the eCRF database periodically after 
interim and final database locks. At the EOS, each site will be given a CD -ROM with all study data entered 
by [CONTACT_30004].  
 | Page 89/107

Protocol   90/[ADDRESS_81185] the S ponso r prior to the destruction of any study 
records or if leaving the institution where the study was conducted. Th e Investigator will notify the S ponsor 
in the event of accidental loss or destruction of any study records.  
12.7.  Deviations from the protocol/protocol  amendments  
As per Sponsor ’s standard practice, in general, no waivers will be granted.  In ca se of medical emergencies, 
the Investigator will use medical judgment and will remove the particip ant from immediate hazard. The 
Sponsor and/or the CRO medical mon itor and the IRB/ IEC will be immediately notified of the type of 
emergency and course of action taken. Permanent changes to or deviations from the protocol will be 
formalized in an amendment to the protocol.  
The ame ndment must be approved by [CONTACT_941] S ponsor, H ealth Authorities and the respective IRB/ IEC prior to 
implementation. If the change implies a modification of treatment or of patient evaluation tests, a new 
version of the ICF must be prepared and submitte d for approval to the IRB. The S ponsor will assume  any 
responsibility or liability resulting from a change in the protocol, only if the change has been approved in 
writing by [CONTACT_74358]/ IEC. 
The Sponsor will promptly notify the relevant Health Authorities, IRB/IEC and/or Investigators, as 
applica ble, of any confirmed serious protocol deviations that may have an impact on subject safety or 
increase the risk/benefit ratio as a result for any participating subjects.  
12.8.  IMP accountability  
The I nvestigator must maintain accurate records o f the IMP(s) rece ived from the S ponsor. These records 
will include receipt, preparation (for nivolumab), and dispensing dates, and dates of return and/or 
destruction of unused supplies.  
At trial termination , clinical supplies must be accounted for and a written clarificat ion provided in case of 
discrepancies. All unused supplies must be properly destroyed at the study site or ret urned promptly to the 
Sponsor; written authori zation from the S ponsor must be obtained prior to destruction which must be 
documented.  
When the ab ove tasks are delegated to a pharmacist, the I nvestigator remains ultimately responsible for the 
maintenance of accurate drug dispensing records.  
12.9.  Study monitoring  
At agreed times during the study and after the study has been comple ted, the I nvestigator wil l let S ponsor 
representatives periodically review the eCRF and corresponding office, hospi[INVESTIGATOR_307], and laboratory records 
(source documents) of each study patient. The eCRFs must be completed by [CONTACT_941] I nvestigator on a regular 
basis and prior to each monitoring visit.  
Monitoring visits allow the S ponsor or a mandated CRO to evaluate study progress, verify accuracy and 
completeness of eCRFs, resolve any inconsistencies in the trial records, and ensure that all protocol 
requirements, applicable l ocal laws, ICH guidelines, and I nvestigator obligations are fulfilled.  
 | Page 90/107

Protocol   91/[ADDRESS_81186] an audit of the study. The purpose of the aud it is to evaluate compliance 
with GCP guidelines, applicable regulatio ns, the study protocol and the S ponsor's procedures, and to assess 
accuracy of the study data.  
Before the audit, the I nvestigator will be contact[CONTACT_74359] a convenien t time for the visit. 
Investigator and staff are expected to be present, co -operate with the auditors, and allow access to all patient 
records supporting the eCRFs, and other study -related documents.  
12.11.  Regulatory agency inspections  
The I nvestigator may unde rgo a Regulatory Agency/IRB/ IEC inspection during the study or after the study 
has been completed. The purpose of such an inspection is to conduct an official review of documents, 
facilities, records, and any other resources that are deemed by [CONTACT_74360] (ies) to be related to the cl inical 
trial.  
The I nvestigator and staff are expected to be available for the inspection and allow access to patient records 
supporting the eCRFs and other study -related documents. If given advance notice of this inspection, the 
Investigator must contact [CONTACT_13130].  
12.12.  Publications  
A scientific communication/paper related to this study will be p ublished as agreed between the S ponsor and 
the Investigator and after review of the final draft by [CONTACT_1034].  
The Investigator will inform the S ponsor in advance about any plans to publish or present data from the 
trial. Any publications and presentations of the results (abstracts in journals or newspapers, oral 
presentations, etc.), either in whole or in part, by I nvestigators or their representatives w ill requir e pre -
submission review by [CONTACT_941] S ponsor.  
12.13.  Insurance policy  
The S ponsor will subscribe a liability insurance covering his and the I nvestigator's responsibility as well as 
the responsibility of any person involved in the conduct of the study, provide d there is proper adherence to 
the protocol. An insurance certi ficate will be provided by [CONTACT_941] S ponsor to the IRB/ IEC if required.  
12.14.  Premature study termination  
The trial may be  prematurely terminated by [CONTACT_941] S ponsor, the I nvestigator, or the IRB/ IEC at any ti me. If 
the study is prematurely terminated, the Investigator must promptly inform the study patients and ensure 
that they receive appropriate therapy and follow -up. All procedures and requirements pertaining to s tudy 
closure as defined by [CONTACT_941] S ponsor will be carried out.  
If the I nvestigator terminates the trial, he/ she should promptly inform the S ponsor and the IRB/ IEC and 
provide a detailed written explanat ion of the termination. If the S ponsor terminates the trial, the I nvestigator 
should promptly inform  the IRB/ IEC and provide a detailed written explanation of the termination. If the 
IRB/ IEC terminates the trial  or suspends its approval, the I nvestiga tor should promptly inform the S ponsor 
and provide a detailed written explanation of the termination.  
 | Page 91/107

Protocol   92/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 13. REFERENCES  
 
1. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four -year survival 
rates for patients with metastatic melanoma who received ipi[INVESTIGATOR_74288]. 
Annals of oncology : official journal of the European Society for Medical Oncology. 
2013;24(8):2174 -80. 
2. Garon E, Leighl N, Rizvi N, al e. Safety and clinical efficacy of MK -3475 in previously treated 
patients (pts) with non -small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(5s):Abst [ADDRESS_81187]. Neoantigens in cancer immunotherapy. Science. 
2015;348(6230):69 -74. 
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved 
survival with ipi[INVESTIGATOR_8612]. The New  England journal of 
medicine. 2010;363(8):[ADDRESS_81188] -line nivolumab (anti -PD-1, BMS -936558, 
ONO4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with 
PD-L1 status J Clin On col 2014;32:abstract 8024.  
6. Gettinger SN, Horn L, Gandhi L, Spi[INVESTIGATOR_43942], Antonia SJ, Rizvi NA, et al. Overall Survival and 
Long -Term Safety of Nivolumab (Anti -Programmed Death 1 Antibody, BMS -936558, ONO -
4538) in Patients With Previously Treated Advanced N on-Small -Cell Lung Cancer. J Clin Oncol. 
2015;33(18):2004 -12. 
7. Jiang Y, Li Y, Zhu B. T -cell exhaustion in the tumor microenvironment. Cell death & disease. 
2015;6:e1792.  
8. Beug ST, Cheung HH, LaCasse EC, Korneluk RG. Modulation of immune signalling by 
[CONTACT_74361]. Trends Immunol. 2012;33(11):535 -45. 
9. Brahmer JR, Drake CG, Wollner I, Powderly JD, Pi[INVESTIGATOR_361] J, Sharfman WH, et al. Phase I study 
of single -agent anti -programmed death -1 (MDX -1106) in refractory solid tumors: safety, clinical 
activity , pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167 -75. 
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activity, and immune correlates of anti -PD-1 antibody in cancer. The New England j ournal of 
medicine. 2012;366(26):2443 -54. 
11. Antonia SJ, Lopez -Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone 
and nivolumab plus ipi[INVESTIGATOR_43869] -cell lung cancer (CheckMate 032): a 
multicentre, open -label, phase 1/2 trial. Lancet Oncol. 2016;17(7):[ADDRESS_81189] 
CHARACTERISTICS. 2018. p. 1 -80. 
13. Champi[INVESTIGATOR_136] S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management 
of immune checkpoint b lockade dysimmune toxicities: a collaborative position paper. Annals of 
oncology : official journal of the European Society for Medical Oncology. 2016;27(4):559 -74. 
14. Tie Y, Ma X, Zhu C, Mao Y, Shen K, Wei X, et al. Safety and efficacy of nivolumab in th e 
treatment of cancers: A meta -analysis of 27 prospective clinical trials. Int J Cancer. 
2017;140(4):948 -58. 
15. Pi[INVESTIGATOR_16611], Hurwitz H, Zanna C, al e. Phase I dose -escalation with extended daily administration 
of Debio 1143, an oral inhibitor of apoptosis pr otein inhibitor, in patients with solid tumors. . J 
Clin Oncol. 2015;33(suppl):abstr 2531.  
16. Kearney CJ, Sheridan C, Cullen SP, Tynan GA, Logue SE, Afonina IS, et al. Inhibitor of 
apoptosis proteins (IAPs) and their antagonists regulate spontaneous and t umor necrosis factor 
(TNF) -induced proinflammatory cytokine and chemokine production. J Biol Chem. 
2013;288(7):4878 -90. 
 | Page 92/107

Protocol   93/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 17. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, et al. IAP inhibitors 
enhance co -stimulation to promote tumor immu nity. The Journal of experimental medicine. 
2010;207(10):2195 -206. 
18. Lecis D, De Cesare M, Perego P, Conti A, Corna E, Drago C, et al. Smac mimetics induce 
inflammation and necrotic tumour cell death by [CONTACT_74362]. Cell death & 
diseas e. 2013;4:e920.  
19. Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, et al. Smac mimetics 
and innate immune stimuli synergize to promote tumor death. Nature biotechnology. 
2014;32(2):182 -90. 
20. Pi[INVESTIGATOR_74289] -Ortiz M, Hastings W, Longmire T, Shaw P , Rong X, Marakami M, et al. The Immune 
Modulatory Roles of IAP Inhibitor, LCL161, and its Connection to Immune Checkpoint 
Molecules.  AACR annual meeting, April 16 -20; New Orleans2016.  
21. Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, et al. Inhibitor of apoptosis 
protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surgery today. 
2011;41(2):[ADDRESS_81190] of multiple 
inhibitor of apoptosis p roteins, inhibits progression of human ovarian cancer. Cancer biology & 
therapy. 2012;13(9):[ADDRESS_81191] (SM -406/AT -406) of multiple inhibitor of apo ptosis proteins (IAPs) in clinical 
development for cancer treatment. Journal of Medicinal Chemistry. 2011;54(8):2714 -26. 
24. Barkhouse D, Tao Z, Myers CJ, al e. The SMAC mimetic Debio 1143 synergizes with 
radiotherapy and immune checkpoint inhibitors to enhance antitumor activity. Mol Cancer Ther ; 
. 2015;14([ADDRESS_81192]. 2):abstr A93.  
25. Hurwitz HI, Smith DC, Pi[INVESTIGATOR_16611], Brill JM, Chugh R, Rouits E, et al. Safety, pharmacokinetics, 
and pharmacodynamic properties of oral DEBIO1143 (AT -406) in patients with adv anced cancer: 
results of a first -in-man study. Cancer chemotherapy and pharmacology. 2015;75(4):[ADDRESS_81193] I, Le Tourneau C, Isambert N, al e. Clinical safety, pharmacokinetics and early 
evidence of activity of the oral IAP inhibitor Debio 1143  in combination with carboplatin and 
paclitaxel: a phase 1 study. Mol Cancer Ther. 2015;14([ADDRESS_81194]. 2):abstr C2.  
27. Le Tourneau C, Tao Y, Delord J -P, Brienza S, Vuagniaux G, Sablin MP, et al. A phase I/II 
randomized study of Debio1143 combined with concu rrent chemoradiation therapy (CCRT) in 
patients with locally advanced squamous cell carcinoma of the head and neck (LA -SCCHN). J 
Clin Oncol. 2014;32(5s (suppl)):abstr TPS6097.  
28. Tao Y, Le Tourneau C, Bouchaab H, al e. Phase 1 study of Debio 1143 with con current chemo -
radiotherapy in locally advanced squamous cell carcinoma of the head and neck. .  ESTRO 35, 
April 29 - May 3 2016; Turin, Italy2016. p. abstr PV -0518.  
29. Juergens RA, Chu QS, Renouf DJ, Laurie SA, Purcea D, McWhirter E, et al. A dose -finding  
study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients 
with advanced solid malignancies. Journal of Clinical Oncology. 2019;37(15_suppl):2599 -. 
30. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to  support the 
rational design of their combinations in cancer immunotherapy. Annals of oncology : official 
journal of the European Society for Medical Oncology. 2018;29(1):71 -83. 
31. George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, et al. Safety and 
Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond 
Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016;2(9):1179 -
86. 
 | Page 93/107

Protocol   94/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 32. Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendo rf D, et al. Nivolumab for 
Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical 
Trials. JAMA Oncol. 2017;3(11):[ADDRESS_81195] -Line Nivolumab 
in Sta ge IV or Recurrent Non -Small -Cell Lung Cancer. The New England journal of medicine. 
2017;376(25):2415 -26. 
34. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 
World Health Organization Classification of Lung Tumors: I mpact of Genetic, Clinical and 
Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official 
publication of the International Association for the Study of Lung Cancer. 2015;10(9):1243 -60. 
35. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. 
Management of Immune -Related Adverse Events in Patients Treated With Immune Checkpoint 
Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin 
Oncol. 2018;36(17):1714 -68. 
36. Rouits E, Csajka C. Debio 1143 population pharmacokinetic analysis. Debiopharm studies 
Debio 1143 -101, Debio 1143 -102 and Debio 1143 -103.; 2016.  
37. Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model -Based Population 
Pharmacokinetic Analysis of N ivolumab in Patients With Solid Tumors. CPT Pharmacometrics 
Syst Pharmacol. 2017;6(1):[ADDRESS_81196] R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (vers ion 1.1). European journal of 
cancer. 2009;45(2):[ADDRESS_81197] 1.1 and CA 
125 ag reed by [CONTACT_74363] (GCIG). Int J Gynecol Cancer. 
2011;21(2):[ADDRESS_81198]: 
guidelines for response criteria for use in trials testing immunotherapeuti cs. Lancet Oncol. 
2017;18(3):e143 -e52. 
41. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade -Lauraine E, Jakobsen A, et al. Re: New 
guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer 
Inst. 2004;96(6):487 -8. 
 
 | Page 94/107

Protocol   95/105 
Debio 1143 -106 
 Copyright Debiopharm International SA  
Final  version No. 4, 03 April 2020  Lausanne, Switzerland  
 14. APPENDICES  
14.1.  Appendix A: World Medical Association Declaration of Helsinki  
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI  
Ethical Principles for Medical Research Involving Human Subjects  
Adopted by [CONTACT_941] 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by [CONTACT_941]:  
29th WMA General Assembly, Tokyo, Japan, October [ADDRESS_81199] WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added)  
55th WMA General Assembly, Tokyo 2004 (Note o f Clarification on Paragraph 30 added)  
59th WMA General Assembly, Seoul, October 2008  
64th WMA General Assembly, Fortaleza, Brazil, October 2013  
PREAMBLE  
 
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethic al 
principles for medical research involving human subjects, including research on identifiable human material 
and data.  
The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied 
without consideration o f all other relevant paragraphs.  
2. Consistent with the mandate of the WMA, the Declaration is addressed primarily to physicians. The WMA 
encourages others who are involved in medical research involving human subjects to adopt these principles.  
GENERAL PRINCI PLES  
3. The Declaration of Geneva of the WMA binds the physician with the words, "The health of my patient will 
be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act 
in the patient's best interest when providing medical care."  
4. It is the duty of the physician to promote and safeguard the health, well -being and rights of patients, including 
those who are involved in medical research. The physician's knowledge and conscience are dedicated to the 
fulfilment of this duty.  
5. Medical progress is based on research that ultimately must include studies involving human subjects.  
6. The primary purpose of medical research involving human subjects is to understand the causes, development 
and effects of diseases and improve  preventive, diagnostic and therapeutic interventions (methods, procedures 
and treatments). Even the best proven interventions must be evaluated continually through research for their 
safety, effectiveness, efficiency, accessibility and quality.  
7. Medical research is subject to ethical standards that promote and ensure respect for all human subjects and 
protect their health and rights.  
8. While the primary purpose of medical research is to generate new knowledge, this goal can never take 
precedence over the ri ghts and interests of individual research subjects.  
9. It is the duty of physicians who are involved in medical research to protect the life, health, dignity, integrity, 
right to self -determination, privacy, and confidentiality of personal information of rese arch subjects. The 
responsibility for the protection of research subjects must always rest with the physician or other health care 
professionals and never with the research subjects, even though they have given consent.  
10. Physicians must consider the ethical , legal and regulatory norms and standards for research involving human 
subjects in their own countries as well as applicable international norms and standards. No national or 
international ethical, legal or regulatory requirement should reduce or eliminat e any of the protections for 
research subjects set forth in this Declaration.  
11. Medical research should be conducted in a manner that minimises possible harm to the environment.  
12. Medical research involving human subjects must be conducted only by [CONTACT_74364], training and qualifications. Research on patients or healthy volunteers requires the 
supervision of a competent and appropriately qualified physician or other health care professional.  
13. Groups that are u nderrepresented in medical research should be provided appropriate access to participation 
in research.  
14. Physicians who combine medical research with medical care should involve their patients in research only to 
the extent that this is justified by [CONTACT_74365], diagnostic or therapeutic value and if the physician 
has good reason to believe that participation in the research study will not adversely affect the health of the 
patients who serve as research subjects.  
15. Appropriate compensation and tr eatment for subjects who are harmed as a result of participating in research 
must be ensured.  
 | Page 95/107

Protocol   96/[ADDRESS_81200], incentives for subjects and 
information regarding provisions for treating and/or compensating subjects who are harmed as a consequence 
of participation in the research study.  
In clinical trials, the protocol must also desc ribe appropriate arrangements for post -trial provisions.  
RESEARCH ETHICS COMMITTEES  
23. The research protocol must be submitted for consideration, comment, guidance and approval to the concerned 
research ethics committee before the study begins. This committee  must be transparent in its functioning, must 
be independent of the researcher, the sponsor and any other undue influence and must be duly qualified. It 
must take into consideration the laws and regulations of the country or countries in which the research  is to be 
performed as well as applicable international norms and standards but these must not be allowed to reduce or 
eliminate any of the protections for research subjects set forth in this Declaration.  
The committee must have the right to monitor ongoing studies. The researcher must provide monitoring 
information to the committee, especially information about any serious adverse events. No amendment to the 
protocol may be made without consideration and approval by [CONTACT_942]. After the end of th e study, the 
researchers must submit a final report to the committee containing a summary of the study’s findings and 
conclusions.  
PRIVACY AND CONFIDENTIALITY  
24. Every precaution must be taken to protect the privacy of research subjects and the confidentialit y of their 
personal information.  
INFORMED CONSENT  
25. Participation by [CONTACT_74366]. Although it may be appropriate to consult family members or community leaders, no individua l 
capable of giving informed consent may be enrolled in a research study unless he or she freely agrees.  
26. In medical research involving human subjects capable of giving informed consent, each potential subject must 
be adequately informed of the aims, method s, sources of funding, any possible conflicts of interest, 
institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the 
discomfort it may entail, post -study provisions and any other relevant aspects of the  study. The potential 
subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate 
at any time without reprisal. Special attention should be given to the specific information needs of individual 
potentia l subjects as well as to the methods used to deliver the information.  
After ensuring that the potential subject has understood the information, the physician or another appropriately 
qualified individual must then seek the potential subject’s freely -given informed consent, preferably in 
 | Page 96/107

Protocol   97/[ADDRESS_81201]’s dissent should be respected.  
30. Research involving subjects who are physically or mentally inc apable of giving consent, for example, 
unconscious patients, may be done only if the physical or mental condition that prevents giving 
informedconsent is a necessary characteristic of the research group. In such circumstances the physician must 
seek inform ed consent from the legally authorised representative. If no such representative is available and if 
the research cannot be delayed, the study may proceed without informed consent provided provided that the 
specific reasons for involving subjects with a co ndition that renders them unable to give informed consent 
have been stated in the research protocol and the study has been approved by a research ethicscommittee. 
Consent to remain in the research must be obtained as soon as possible from the subject or a legally authorised 
representative.  
31. The physician must fully inform the patient which aspects of their care are related to the research. The refusal 
of a patient to participate in a study or the patient’s decision to withdraw from the study must never adver sely 
affect the patient -physician relationship.  
32. For medical research using identifiable human material or data, such as research on material or data contained 
in biobanks or similar repositories, physicians must seek informed consent for its collection, st orage and/or 
reuse. There may be exceptional situations where consent would be impossible or impracticable to obtain for 
such research. In such situations the research may be done only after consideration and approval of a research 
ethics committee.  
USE OF  PLACEBO  
33. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best 
proven intervention(s), except in the following circumstances:  
Where no proven intervention exists, the use of placebo, or no interventi on, is acceptable; or  
Where for compelling and scientifically sound methodological reasons the use of any intervention less 
effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy 
or safety of an intervention and the pat ients who receive any intervention less effective than the best proven 
one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm as a result 
of not receiving the best proven intervention.  
Extreme care must be  taken to avoid abuse of this option.  
POST -TRIAL PROVISIONS  
34. In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for 
post-trial access for all participants who still need an intervention identified as be neficial in the trial. This 
information -must also be disclosed to participants during the informed consent process.  
RESEARCH REGISTRATION AND PUBLICATION AND DISSEMINATION OF RESULTS  
35. Every research study involving human subjects must be registered in a pu blicly accessible database before 
recruitment of the first subject.  
36. Researchers, authors, sponsors, editors and publishers all have ethical obligations with regard to the 
publication and dissemination of the results of research. Researchers have a duty to make publicly available 
the results of their research on human subjects and are accountable for the completeness and accuracy of their 
reports. All parties should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as 
well as pos itive results must be published or otherwise made publicly available. Sources of funding, 
institutional affiliations and conflicts of interest must be declared in the publication. Reports of research not 
in accordance with the principles of this Declaratio n should not be accepted for publication.  
UNPROVEN INTERVENTIONS IN CLINICAL PRACTICE  
37. In the treatment of an individual patient, where proven interventions do not exist or other known interventions 
have been ineffective, the physician, after seeking expert  advice, with informed consent from the patient or a 
legally authorised representative, may use an unproven intervention if in the physician's judgement it offers 
hope of saving life, re -establishing health or alleviating suffering. This intervention shoul d subsequently be 
 | Page 97/107
